ciprofloxacin has been researched along with moxifloxacin in 390 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 14 (3.59) | 18.2507 |
| 2000's | 207 (53.08) | 29.6817 |
| 2010's | 135 (34.62) | 24.3611 |
| 2020's | 34 (8.72) | 2.80 |
| Authors | Studies |
|---|---|
| Inagaki, H; Kawakami, K; Kawato, HC; Matsuhashi, N; Miyauchi, RN; Miyauchi, S; Ohki, H; Takahashi, H; Takemura, M | 1 |
| Keserü, GM | 1 |
| Gibbons, S; Kaatz, GW; Zloh, M | 1 |
| Baroni, M; Cecchetti, V; Cianchetta, G; Cruciani, G; Mannhold, R | 1 |
| Nagashima, R; Nishikawa, T; Tobita, M | 1 |
| Jolivette, LJ; Ward, KW | 1 |
| Jolivette, LJ; Nagilla, R; Ward, KW | 1 |
| Appelbaum, PC; Bhawsar, SB; Bozdogan, B; de Souza, NJ; Desai, VN; Deshpande, PK; Gupte, SV; Hooper, DC; Jacobs, MR; Jha, R; Khorakiwala, HF; Patel, MV; Shetty, N; Shukla, MC; Strahilevitz, J; Yeole, RD | 1 |
| Bradbury, BJ; Cheng, J; Deshpande, M; Hashimoto, A; Lucien, E; Marlor, CW; Ou, Y; Podos, SD; Pucci, MJ; Song, Y; Thanassi, JA; Thoma, CL; Wang, Q; Wiles, JA | 2 |
| Choi, TY; Pai, H; Seo, MR | 1 |
| Duewelhenke, N; Eysel, P; Krut, O | 1 |
| Arpin, C; Ba, BB; Caignard, DH; Forfar-Bares, I; Grellet, J; Guillon, J; Jarry, C; Moreau, S; Quentin, C; Vidaillac, C | 1 |
| Klugman, KP; Levin, BR; McGee, L; Rozen, DE | 1 |
| Balasubramanian, V; Bharath, S; Gaonkar, S; Jayaram, R; Jayashree, R; Kaur, P; Mahesh, BN; Nandi, V; Shandil, RK; Suresh, BL | 1 |
| Cho, SH; Franzblau, SG; Hwang, CH; Pauli, GF; Wan, B; Warit, S | 1 |
| Black, JA; Hanson, ND; Hong, SG; Hossain, A; Moland, ES; Thomson, KS; Wickman, PA | 1 |
| Bradbury, BJ; Buechter, DD; Cheng, J; Deshpande, M; Hashimoto, A; Lucien, E; Marlor, CW; Nelson, DM; Ou, Y; Pais, GC; Podos, SD; Pucci, MJ; Song, Y; Thanassi, JA; Thoma, CL; Wang, Q; Wiles, JA | 1 |
| Bradbury, BJ; Buechter, DD; Cheng, J; Deshpande, M; Mushtaq, G; Podos, SD; Pucci, MJ; Thanassi, JA; Thoma, CL; Vigliotti, GA | 1 |
| Campos, J; García-Cobos, S; Pérez-Vázquez, M; Román, F | 1 |
| Aubry, A; Cambau, E; Jarlier, V; Matrat, S; Petrella, S; Sougakoff, W | 1 |
| Cano, ME; García, I; Martínez-Martínez, L; Pascual, A; Rodríguez-Martínez, JM; Velasco, C | 1 |
| Cattoir, V; Mazel, D; Nordmann, P; Poirel, L; Soussy, CJ | 1 |
| Courvalin, P; Galimand, M; Périchon, B | 1 |
| Bradbury, BJ; Cheng, J; Deshpande, M; Pucci, MJ; Thanassi, JA; Thoma, CL | 1 |
| Cattoir, V; Nordmann, P; Poirel, L | 2 |
| Arakawa, Y; Kato, H; Kimura, K; Konda, T; Shibata, N; Shibayama, K; Suzuki, S; Wachino, J; Yamane, K | 1 |
| Adams, DA; Donskey, CJ; Riggs, MM | 1 |
| Arsène, S; Leclercq, R | 1 |
| Morgan-Linnell, SK; Zechiedrich, L | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Calvet, L; Devine, R; Dubreuil, L; Jean-Pierre, H; Jumas-Bilak, E; Marchandin, H; Mercier, G; Morio, F | 1 |
| Andres, P; Centrón, D; Galas, M; Guerriero, L; Petroni, A; Quiroga, C; Quiroga, MP; Soler Bistué, AJ; Tokumoto, M; Tolmasky, ME; Vargas, LJ; Zorreguieta, A | 1 |
| Appelbaum, PC; Bogdanovich, T; Clark, C; Dewasse, B; Ednie, L; McGhee, P; Smith, K | 1 |
| Bitting, C; Gruppo, V; Johnson, CM; Lenaerts, AJ; Marietta, KS; Orme, IM; Woolhiser, L | 1 |
| Baudry, PJ; DeCorby, M; Hoban, DJ; Johnson, J; Karlowsky, JA; Lagacé-Wiens, P; Laing, N; McCracken, M; Mulvey, MR; Nichol, KA; Tailor, F; Vashisht, R; Walkty, A; Weshnoweski, B; Wierzbowski, A; Zhanel, GG | 1 |
| Ho, YR; Hung, KH; Janapatla, RP; Wu, CW; Wu, HM; Wu, JJ; Yan, JJ | 1 |
| Desroches, MC; Grayo, S; Join-Lambert, O; Le Monnier, A | 1 |
| Beckius, ML; Fraser, SL; Galloway, RL; Griffith, ME; Hospenthal, DR; Mende, K; Miller, RS; Murray, CK; Pimentel, G; Ressner, RA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Jia, L; Sun, H | 1 |
| Hiramatsu, K; Kikuchi, K; Ohtsuka, M; Ono, Y; Sasaki, T; Shimizu, K; Takahashi, N | 1 |
| Crabb, DM; Duffy, LB; Waites, KB | 1 |
| Baines, SD; Freeman, J; O'Connor, R; Saxton, K; Wilcox, MH | 1 |
| del Pozo, JL; Mandrekar, JN; Patel, R; Rouse, MS; Sampedro, MF; Steckelberg, JM | 1 |
| Bremont, S; Charavay, F; Courvalin, P; Goarant, C; Le Hello, S; O'Connor, O; Page, S; Vernel-Pauillac, F | 1 |
| Drlica, K; German, N; Kerns, RJ; Malik, M; Rosen, JD | 1 |
| Arhin, FF; Caron, L; Delorme, D; Dietrich, E; Fadhil, I; Ferreira, SS; Houghton, TJ; Kang, T; Laquerre, K; Lehoux, D; Liu, J; Moeck, G; Ostiguy, V; Parr, TR; Poirier, H; Rafai Far, A; Sarmiento, I; Tanaka, KS; Viens, F | 1 |
| Arhin, FF; Delorme, D; Dietrich, E; Fadhil, I; Far, AR; Ferreira, SS; Houghton, TJ; Kang, T; Lafontaine, Y; Laquerre, K; Lehoux, D; Liu, J; Moeck, G; Ostiguy, V; Parr, TR; Poirier, H; Sarmiento, I; Tanaka, KS; Viens, F | 1 |
| Cavazos-Rocha, N; Chacon-Moreno, BE; de la Luz Salazar-Cavazos, M; Garza-Lozano, HG; Ocampo-Candiani, J; Said-Fernandez, S; Vera-Cabrera, L; Welsh, O | 1 |
| Li, W; Liu, Y; Wang, M; Xu, X; Ye, X; Zhang, H; Zhu, D | 1 |
| Choi, SH; Jeong, JY; Jun, JB; Kim, ES; Kim, MN; Kim, YS; Lee, SO; Woo, JH | 1 |
| Appelbaum, PC; Ednie, LM; Kosowska-Shick, K; McGhee, P | 1 |
| Chlipala, G; Krunic, A; Mo, S; Orjala, J | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Hirakata, Y; Imamura, Y; Izumikawa, K; Kakeya, H; Kamihira, S; Kohno, S; Seki, M; Sugahara, K; Yamamoto, K; Yamamoto, Y; Yanagihara, K | 1 |
| Brunner, LS; Haas, W; Lee, JC; Morris, TW; Pillar, CM; Zurenko, GE | 1 |
| Dionisi, AM; Lucarelli, C; Luzzi, I; Owczarek, S; Villa, L | 1 |
| Azéma, J; Dewelle, J; Guidetti, B; Kiss, R; Korolyov, A; Le Calve, B; Malet-Martino, M; Martino, R; Mijatovic, T; Vaysse, J | 1 |
| Caddick, JM; Gunell, M; Hakanen, AJ; Huovinen, P; Jalava, J; Kotilainen, P; Lilly, AJ; Piddock, LJ; Siitonen, A; Webber, MA | 1 |
| Inagaki, H; Ito, M; Kawakami, K; Matsuhashi, N; Miyauchi, R; Ohki, H; Takahashi, H; Takemura, M | 1 |
| Ekambaram, R; Raghunathan, M; Raghunathan, R; Rao, SS | 1 |
| Adam, HJ; Hoban, DJ; King, CR; Laing, NM; Lulashnyk, B; Zhanel, GG | 1 |
| Hamasuna, R; Jensen, JS; Osada, Y | 1 |
| Larruskain, J; Montes, M; Orden, B; Perez-Trallero, E; Tamayo, E | 1 |
| Brillault, J; Couet, W; De Castro, WV | 1 |
| Martínez, JL; Sánchez, MB | 1 |
| Anquetin, G; Biot, C; Dive, D; Dubar, F; Khalife, J; Pradines, B | 1 |
| Appelbaum, PC; Credito, K; Kosowska-Shick, K; McGhee, P; Pankuch, GA | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Hakanen, AJ; Huovinen, P; Kotilainen, P; Lehtopolku, M; Nakari, UM; Siitonen, A | 1 |
| Chen, HC; King, CH; Lai, JF; Lauderdale, TL; Shiau, YR | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Amsler, KM; Bush, K; Foleno, BD; He, W; Lynch, AS; Macielag, MJ; Morrow, BJ | 1 |
| Ardanuy, C; Brito-Avô, A; Gonçalo-Marques, J; Liñares, J; Morais, A; Pires, R; Rolo, D; Santos-Sanches, I | 1 |
| Barber, M; Eberly, LE; Feeney, LA; Miller, GH; Summers, A; Wortmann, G; Zapor, MJ | 1 |
| Brincat, JP; Carosati, E; Dimovska, M; Fravolini, A; Kaatz, GW; Massari, S; Pieroni, M; Sabatini, S | 1 |
| Al-Trawneh, SA; Alfieri, RR; Cavazzoni, A; El-Abadelah, MM; Incerti, M; Kamal, MR; Petronini, PG; Vicini, P; Zahra, JA; Zani, F | 1 |
| Baek, SY; Chae, SE; Cho, YL; Jeong, JW; Jung, SJ; Kim, YZ; Kwak, JH; Lee, HH; Lee, HS; Park, TK; Woo, SH | 1 |
| Hamprecht, A; Higgins, PG; Schneiders, T; Seifert, H | 1 |
| Briales, A; Díaz de Alba, P; Domínguez-Herrera, J; Pachón, J; Pascual, A; Rodríguez-Martínez, JM; Velasco, C | 1 |
| Sen, S; Sinha, N | 1 |
| Bradbury, BJ; Deshpande, M; Hashimoto, A; Kim, HY; Lucien, E; Nelson, DM; Pais, GC; Podos, SD; Pucci, MJ; Thanassi, JA; Wang, Q; Wiles, JA | 1 |
| Bradbury, BJ; Deshpande, M; Phadke, AS; Pucci, MJ; Thanassi, JA; Wiles, JA | 1 |
| Al-Taweel, SA; Al-Trawneh, SA; Cavazzoni, A; El-Abadelah, MM; Incerti, M; Vicini, P; Zahra, JA; Zani, F | 1 |
| Drlica, K; Hiasa, H; Kerns, RJ; Malik, M; Marks, KR; Mustaev, A | 1 |
| Feng, LS; Guo, HQ; Liu, ML; Lv, K; Sun, LY; Sun, YX; Wei, ZQ | 1 |
| Chovatia, PT; Parekh, HH; Pathak, RB | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Anquetin, G; Aubry, A; Capton, E; Gomez, C; Jarlier, V; Lamouri, A; Pantel, A; Ponien, P; Serradji, N | 1 |
| Inagaki, H; Kitamura, T; Komoriya, S; Kuroyanagi, J; Miyauchi, RN; Nagamochi, M; Odagiri, T; Sugimoto, Y; Takahashi, H | 1 |
| Imai, YN; Oiki, S; Ryu, S | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, L; Fan, L; He, ZQ; Jiang, L; Lei, HS; Liu, CP; Liu, J; Peng, XM; Xu, XR; Yang, DC; Zhou, CH; Zhou, FW; Zou, YY | 1 |
| Achar, V; Arora, U; Awasthy, D; Bharath, S; Bheemarao, U; Chinnapattu, M; Coulson, M; de Sousa, SM; Ganguly, S; Gaonkar, S; Ghosh, A; Hameed P, S; Hoffner, S; Humnabadkar, V; Kaur, P; Kumar K N, M; Kumar, CN; Madhavapeddi, P; Manjrekar, P; Menasinakai, S; Mukherjee, K; Nandishaiah, R; Narayan, C; Panduga, V; Patil, V; Puttur, J; Raichurkar, A; Ramya, VK; Reddy, J; Rudrapatana, S; Sambandamurthy, VK; Shanbhag, G; Sharma, S; Sharma, U; Shinde, V; Solapure, S; Waterson, D; Werngren, J | 1 |
| Hameed P, S; Kaur, P; Madhavapeddi, P; Menasinakai, S; Nandishaiah, R; Panduga, V; Raichurkar, A; Reddy, J; Sambandamurthy, VK; Sharma, S; Sriram, D | 1 |
| Guo, H; Huang, J; Liu, H; Liu, M; Lu, Y; Wang, B; Wang, J; Wang, M | 1 |
| Chinnapattu, M; Hameed P, S; Kumar, CN; Madhavapeddi, P; Manjrekar, P; Nandishaiah, R; Patil, V; Puttur, J; Raichurkar, A; Rudrapatana, S; Sambandamurthy, VK; Shanbhag, G; Sharma, S; Shinde, V; Solapure, S; Sriram, D | 1 |
| Bao, Y; Huang, X; Lan, S; Wang, T; Zhang, X; Zhu, S | 1 |
| Huang, J; Li, L; Liu, H; Liu, M; Lu, Y; Wang, B; Wang, C; Wang, M; Zhang, R | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Feng, L; Huang, J; Li, X; Liu, M; Lu, Y; Wang, B; Wang, M; Wu, Z; Yang, Y; Zhang, J | 1 |
| Daletos, G; Ebrahim, W; El-Neketi, M; Kalscheuer, R; Lewald, LI; Lin, W; Orfali, RS; Proksch, P; Rehberg, N | 1 |
| Lynch, AS; Ma, Z | 1 |
| Fernando, DM; Gorityala, BK; Goswami, S; Guchhait, G; Kumar, A; Schweizer, F; Zhanel, GG | 1 |
| Acar Çevik, U; Gençer, HK; Ilgın, S; Levent, S; Özkay, Y | 1 |
| Domalaon, R; Gorityala, BK; Goswami, S; Idowu, T; Lyu, Y; Schweizer, F; Shan, A; Yang, X; Zhanel, GG | 1 |
| Cvijetić, IN; Drakulić, BJ; Ernesto de Resende, P; Gibbons, S; Juranić, IO; Stapleton, P; Verbić, TŽ; Zloh, M | 1 |
| Cheng, XW; Fan, YL; Feng, LS; Wu, JB; Zhang, FZ | 1 |
| Almstead, NG; Arnold, MA; Baird, J; Branstrom, AA; Chen, G; Dumble, M; Gerasyuto, AI; Karp, GM; Narasimhan, J; Peddi, S; Prasad, JVN; Sheedy, J; Smith, S; Wang, J; Weetall, M; Woll, MG; Zhang, N; Zhang, X | 1 |
| Inagaki, H; Kitamura, T; Komoriya, S; Nagamochi, M; Odagiri, T; Takahashi, H | 1 |
| Eswaran, S; Narayanan, S; Shivarudraiah, P; Shruthi, TG; Subramanian, S | 1 |
| Bai, L; Deng, JL; Gao, F; Lv, ZS; Wang, Y; Xu, Z; Zhang, F; Zhao, SJ | 1 |
| Berry, L; Brizuela, M; Domalaon, R; Schweizer, F; Zhanel, GG | 1 |
| Ciura, K; Fallarero, A; Fedorowicz, J; Gilbert-Girard, S; Konopacka, A; Lejnowski, D; Morawska, M; Sączewski, J; Savijoki, K; Skok, Ž; Tomašič, T; Waleron, K | 1 |
| Caljon, G; Cappoen, D; Claes, P; Cools, F; Cos, P; De Kimpe, N; de Macedo, MB; Delputte, P; Holvoet, F; Maes, L; Mangelinckx, S; Matheeussen, A; Meiresonne, T; Neyrolles, O; Piller, T; Semina, E; Torfs, E; Van Calster, K | 1 |
| Blaskovich, MAT; Pham, TDM; Ziora, ZM | 1 |
| Bangalore, PK; Bollikanda, RK; Choudante, PC; Kantevari, S; Misra, S; Sridhar, B; Sriram, D; Vagolu, SK; Veeragoni, DK | 1 |
| Krishna, VS; Sirim, MM; Sriram, D; Unsal Tan, O | 1 |
| Dana, S; Dhar, SK; Gurung, SK; Kumar, S; Mondal, N; Mukhopadhyay, P; Valissery, P | 1 |
| Betson, M; Bingham, M; Doyle, P; Hallworth, S; Harvey, R; Huxley, A; Kirk, R; Moat, J; Nelson, G; Pesnot, T; Tait, M | 1 |
| Anquetin, G; Aubry, A; Bercot, B; Chauffour, A; Gomez, C; Mainardis, M; Mayer, C; Sachon, E; Sadowski, E; Sougakoff, W; Varon, E | 1 |
| Brady, SF; Koirala, B; Peek, J | 1 |
| Bhagwat, S; Bhawsar, S; Deshpande, P; Joshi, S; Patel, M; Yeole, R | 1 |
| Bauernfeind, A | 1 |
| Hoban, DJ; Karlowsky, JA; Zhanel, GG | 1 |
| Dalhoff, A; Hoppe, JE; Pfründer, D | 1 |
| Al-Nawas, B; Shah, PM | 1 |
| Ballesta, S; García, I; Pascual, A; Perea, EJ | 1 |
| Heisig, P; Jones, ME; Klootwijk, M; Schmitz, FJ; Verhoef, J; Visser, MR | 1 |
| Engler, B; Fluit, AC; Hadding, U; Heinz, HP; Hofmann, B; Jones, ME; Lückefahr, M; Schmitz, FJ; Verhoef, J | 1 |
| Balfour, JA; Wiseman, LR | 1 |
| Dalhoff, A; Ruckdeschel, G | 1 |
| Jin, YF; Piddock, LJ | 1 |
| Barry, AL; Brown, SD; Fuchs, PC | 1 |
| Bianco, G; Capone, A; Cassone, M; Tarasi, A; Tarasi, D; Venditti, M | 1 |
| Brisse, S; Fluit, AC; Köhrer, K; Martin, N; Milatovic, D; Scheuring, S; Schmitz, FJ; Verhoef, J | 1 |
| Chartrand, SA; Moland, ES; Pong, A; Sanders, CC; Thomson, KS | 1 |
| Amsterdam, D; Hardy, D; Mandell, LA; Rotstein, C | 1 |
| Edmond, M; Heinemann, B; Seifert, H; Wisplinghoff, H | 1 |
| Brayson, J; Fawley, W; Freeman, J; Wilcox, MH | 1 |
| Fraser, S; Mair, D; Patmore, L; Templeton, A | 1 |
| Hollauer, K; Kirchbauer, D; Naber, KG; Witte, W | 1 |
| Ahr, G; Andresen, P; Blaschke, G; Grünefeld, G; Möller, JG; Schierenberg, MO; Schulz, H; Soetebeer, UB | 1 |
| Doern, GV; Ernst, EJ; Klepser, ME; Petzold, CR; Rhomberg, P | 1 |
| Hedges, AJ; MacGowan, AP; Sunderland, J; Tobin, CM; White, LO | 1 |
| George, RC; Johnson, AP; Livermore, DM; Warner, M | 1 |
| Climent, A; Rodríguez, JC; Royo, G; Ruiz, M | 1 |
| Barzilai, A; Diamantstein, L; Gruzman, G; Keller, N; Rubinovitch, B; Rubinstein, E; Yoseph, G | 1 |
| Berrington, AW; Gould, FK; Perry, JD | 1 |
| Johnson, AP; Livermore, DM; Warner, M | 1 |
| Everett, D; Gillespie, SH; Morrissey, I | 1 |
| Biedenbach, DJ; Jones, RN; Pfaller, MA | 1 |
| Appelbaum, PC; Davies, T; Edlund, C; El Amin, N; Oh, H | 1 |
| Fabian, I; Halperin, D; Kletter, Y; Nagler, A; Shalit, I; Vasserman, E; Waldman, D | 1 |
| Appelbaum, PC; Davies, TA; Dewasse, BE; Jacobs, MR; Nagai, K | 1 |
| Andrews, JM; Boswell, FJ; Wise, R | 1 |
| Georgopoulos, A; Graninger, W; Grisold, A; Mueller-Uri, P; Presterl, E | 1 |
| Entenza, JM; Glauser, MP; Moreillon, P; Que, YA; Vouillamoz, J | 1 |
| Ambler, J; Cardeñosa, O; Lemme, L; Lopez, H; Scarano, S; Smayevsky, J; Stepanik, D; Sucari, A; Vilches, V | 1 |
| Piddock, LJ; Ricci, V | 1 |
| Arias-Puente, A; Carrasco-Font, C; Fresnadillo-Martinez, MJ; García-Sáenz, MC | 1 |
| Bachoual, R; Lascols, C; Mory, F; Ouabdesselam, S; Soussy, CJ; Tankovic, J | 1 |
| Frothingham, R | 2 |
| Blondeau, JM | 1 |
| Blandino, G; Caccamo, F; Milazzo, I; Musumeci, R; Nicoletti, G; Speciale, A | 1 |
| Bébéar, C; Bébéar, CM; Charron, A; Gonzalez, P; Raherison, S; Renaudin, H | 1 |
| Calvo, A; García, R; Gómez-Lus, ML; Leturia, A; Sevillano, D; Valero, E | 1 |
| Picazo, JJ; Rodríguez-Avial, C; Rodríguez-Avial, I | 1 |
| Karenchak, LM; Kowalski, RP; Mather, R; Romanowski, EG | 1 |
| Brandenburg, K; Dalhoff, A; Lindner, B; Seydel, U; Wiese, A | 1 |
| Carryn, S; Mingeot-Leclercq, MP; Tulkens, PM; Van Bambeke, F | 1 |
| Appelbaum, PC; Bozdogan, B; Clark, CL; Davies, TA; Dewasse, B; Jacobs, MR; Nagai, K | 1 |
| Barbut, F; Burghoffer, B; Dridi, L; Petit, JC; Tankovic, J | 1 |
| Aktaş, Z; Anğ, O; Bal, C; Gönüllü, N; Salcioğlu, M | 1 |
| Behra-Miellet, J; Dubreuil, L; Jumas-Bilak, E | 1 |
| Cheong, HJ; Choo, YS; Kang, MW; Kim, WJ; Kim, YS; Lee, KW; Park, YJ; Woo, JH; Yong, DE | 1 |
| Bello, S; Torres, A | 1 |
| Hooper, DC; Ince, D; Zhang, X | 1 |
| Firsov, AA; Lubenko, IY; Portnoy, YA; Vostrov, SN; Zinner, SH | 1 |
| Abels, R; Chien, S; Goodman, DB; Hunt, TL; Natarajan, J; Noel, GJ | 1 |
| Dalhoff, A; Shalit, I | 1 |
| Chiang, SR; Chuang, YC; Ko, WC; Lee, HC; Tang, HJ; Wang, YY | 1 |
| Seral, C; Tulkens, PM; Van Bambeke, F | 1 |
| Eisenblätter, M; Hahn, H; Ignatius, R; Jabbusch, M; Wagner, J; Wendt, C | 1 |
| Aguilar, L; Garcia-Mendez, E; Jiménez De Anta, MT; Marco, F; Mensa, J; Ruiz, J; Sierra, JM; Vila, J | 1 |
| Carter, O; Counts, C; Dodson, S; Lody, C; Madhusudhan, KT; Ojha, N | 1 |
| Piddock, L; Ricci, V | 1 |
| Dhaliwal, DK; Gordon, YJ; Karenchak, LM; Kowalski, RP; Mah, FS; Ritterband, DC; Romanowski, EG | 1 |
| Ciottoli, GB; Crumb, WJ; Durando, L; Lacroix, P | 1 |
| Leggett, J; Saravolatz, LD | 1 |
| Arpin, C; Ba, BB; Feghali, H; Quentin, C; Saux, MC | 1 |
| Aracil, B; Campos, J; Cantón, R; Pérez-Vázquez, M; Román, F | 1 |
| Choo, CM; Lim, T; Lim, YS; Ngan, CC; Toh, GL | 1 |
| Elliott, MA; Patel, R; Prabhu, RM | 1 |
| Dajcs, JJ; Girgis, DO; Marquart, ME; O'Callaghan, RJ; Thibodeaux, BA; Traidej, M | 1 |
| Brooks, TJ; Lever, MS; Sefton, AM; Simpson, AJ; Steward, J | 1 |
| Grohs, P; Gutmann, L; Podglajen, I | 1 |
| Caballero, AR; Dajcs, JJ; Girgis, DO; Marquart, ME; O'Callaghan, RJ; Thibodeaux, BA | 1 |
| Cardeñosa, O; Contreras-Rodríguez, A; Gutiérrez-Rubio, AT; Hernández-Oliva, GM; López-Merino, A; Migranas-Ortiz, R; Orrantia-Gradín, R | 1 |
| Charles, PE; Chavanet, P; Croisier, D; Drlica, K; Etienne, M; Lequeu, C; Piroth, L; Portier, H | 1 |
| Drlica, K; Li, X; Mariano, N; Rahal, JJ; Urban, CM | 1 |
| Aguilar, L; Alkorta, M; Giménez, MJ; Pérez-Trallero, E; Vicente, D | 1 |
| Aliprandis, E; Ciralsky, J; Herling, I; Katz, HR; Lai, H | 1 |
| Barcia-Macay, M; Mingeot-Leclercq, MP; Seral, C; Tulkens, PM; Van Bambeke, F | 1 |
| Brooks, TJ; Lever, MS; Nelson, M; Piercy, T; Simpson, AJ; Steward, J | 1 |
| Bloom, A; Donnenfeld, ED; Nedrud, C; Perry, HD; Snyder, RW; Solomon, R; Stein, J | 1 |
| Holzgrabe, U; Kiefer, W; Neugebauer, U; Popp, J; Schmitt, M; Szeghalmi, A | 1 |
| Bogner, JR; Draenert, R; Hellers, J; Kunzelmann, M; Roggenkamp, A | 1 |
| Cheng, HJ; Hsueh, PR; Tang, JL; Tien, HF; Yao, M | 1 |
| Michot, JM; Mingeot-Leclercq, MP; Seral, C; Tulkens, PM; Van Bambeke, F | 1 |
| Paramasivan, CN; Rahman, F; Sulochana, S | 1 |
| Galley, HF; Watt, AM; Webster, NR; Williams, AC | 1 |
| Cabeza, JG; Hernandez, J; Llagostera, M; Mensa, J; Montero, T; Ruiz Chaler, M; Sierra, JM; Vila, J | 1 |
| Abelson, MB; Shapiro, A; Torkildsen, G; Wagner, RS | 1 |
| Jung, HC; Kim, JM; Kim, JS; Kim, N; Song, IS | 1 |
| Marchese, A; Roveta, S; Schito, AM; Schito, GC | 1 |
| Brooks, TJ; Lever, MS; Piercy, T; Steward, J | 1 |
| Bolduc, DL; Brook, I; Camp-Hyde, TD; Elliott, TB; Foriska, MA; Germana, A; Giraldo, DE; Jackson, WE; Ledney, GD; Shoemaker, MO; Thakar, JH | 1 |
| Depta, JP; Pichler, WJ; Schmid, DA | 1 |
| Caballero, AR; Dajcs, JJ; Johnston, KH; Marquart, ME; O'Callaghan, RJ; Thibodeaux, BA | 1 |
| Cox, CD; Meyerrose, GE; Peeters, MJ; Seifert, CF; Tsikouris, JP | 1 |
| Drobniewski, FA; Krüüner, A; Yates, MD | 1 |
| Dalhoff, A | 1 |
| Berger, J; Döring, G; Möller, JG; Ulrich, M | 1 |
| Lück, PC; Steinert, M | 1 |
| Brooks, TJ; Lever, MS; Piercy, T; Simpson, AJ; Steward, J | 1 |
| García, I; Martínez-Martínez, L; Pascual, A; Rodríguez-Martínez, JM; Velasco, C | 1 |
| Appelbaum, PC; Bozdogan, B; Choi, DR; Credito, K; Dewasse, B; Kosowska-Shick, K; Lin, G; McGhee, P; Pankuch, GA; Ryu, JM | 1 |
| Black, JA; Moland, ES; Thomson, KS; Wickman, PA | 1 |
| Bayar, B; Bozkurt, A; Dinçel, A; Duman, S; Kaya, E; Oflu, Y; Yağci, R; Yağci, S | 1 |
| Aydemir, S; Cilli, F; Tunger, A | 1 |
| Cebrian, L; Escribano, I; Pertegás, V; Rodríguez, JC; Royo, G | 1 |
| Blau, H; Fabian, I; Halperin, D; Klein, K; Shalit, I | 1 |
| Black, JA; Hanson, ND; Smith Moland, E; Thomson, KS; Wickman, PA | 1 |
| Adam, HJ; Baudry, TJ; Hoban, CJ; Hoban, DJ; Laing, NM; Nichol, KA; Schurek, KN; Zhanel, GG | 1 |
| Fiscella, RG; Jensen, MK | 1 |
| Rodríguez, JC; Royo, G; Ruiz, M; Sirvent, E | 1 |
| D'Azevedo, PA; Francisco, W; Oliveira, AD | 1 |
| Amyes, SG; Dobay, O; Ghidán, A; Matuz, M; Nagy, K; Rozgonyi, F | 1 |
| Catero, M | 1 |
| Haggerty, CL; Ness, RB | 1 |
| Breithardt, G; Cakir, Y; Eckardt, L; Engelen, MA; Haverkamp, W; Hilker, E; Milberg, P; Mönnig, G; Osada, N; Ramtin, S; Stypmann, J | 1 |
| Blondeau, JM; Borsos, S; Hesje, CK | 1 |
| Blondeau, JM; Hedlin, P | 1 |
| Buxbaum, A; Georgopoulos, A; Graninger, W; Kratzer, C; Macfelda, K | 1 |
| Choi, EC; Choi, JS; Joo, CK; Kim, SY; Lim, JA | 1 |
| Cox, SK | 1 |
| Bezwada, P; Clark, LA; Schneider, S | 1 |
| Bensikaddour, H; Brasseur, R; Burton, I; Deleu, M; Dufrêne, YF; Fa, N; Goormaghtigh, E; Lins, L; Mingeot-Leclercq, MP; Schanck, A | 1 |
| Fabian, I; Halperin, D; Priel, E; Reuveni, D; Shalit, I | 1 |
| Chang, ST; Chen, CC; Cheng, KC; Chuang, YC; Huang, HC; Shieh, CC; Yu, WL | 1 |
| Carroll, DG; Carroll, DN | 1 |
| Jagielski, M; Piekarska, K | 1 |
| Lindsell, C; Ryan, RJ; Sheehan, P | 1 |
| Galani, I; Giamarellos-Bourboulis, EJ; Giamarellou, H; Kanellakopoulou, K; Sarafis, P | 1 |
| Courvalin, P; Lismond, A; Mingeot-Leclercq, MP; Tulkens, PM; Van Bambeke, F | 1 |
| Gierczyński, R; Jagielski, M; Kochman, M; Piekarska, K; Ławrynowicz-Paciorek, M | 1 |
| Arias, CA; Cárdenas, AM; Castañeda, E; Díaz, L; Díaz, PL; Hidalgo, M; Reyes, J; Rincón, S; Vanegas, N | 1 |
| Fiscella, RG; Jensen, MK; Mooney, B; Moshirfar, M | 1 |
| Asbell, PA; Epstein, SP; Sosa, AB | 1 |
| Horstkotte, MA; Knobloch, JK; Mack, D; Rohde, H; Von Osten, H | 1 |
| Qi, HM; Wei, MJ; Zhang, L; Zhao, CY | 1 |
| Choi, JS; Joo, CK; Kim, KA; Lim, JA; Park, SH | 1 |
| Meletiadis, J; Papaioannidou, P; Roilides, E; Sein, T; Stergiopoulou, T; Tsiouris, I; Walsh, TJ | 1 |
| Holland, EJ; Lane, SS; Lindstrom, RL | 1 |
| McCulley, JP | 1 |
| Alam, MR; Garg, P; Gopinathan, U; Krishnaiah, S; Reddy, AK; Sharma, S | 1 |
| Galley, HF; Lowes, DA; Murphy, MP; Wallace, C; Webster, NR | 1 |
| García-Rodríguez, JA; Lázaro, FG; Muñoz-Bellido, JL; Rodríguez-Tarazona, RE | 1 |
| Boussery, K; Colpaert, K; De Paepe, P; De Smet, J; De Sutter, P; Decruyenaere, J; Van Bocxlaer, J | 1 |
| Chapelle, S; Goossens, H; Lammens, C; Malhotra-Kumar, S; Van Heirstraeten, L | 1 |
| Bhadresa, S; Coon, DJ; Lawrence, MS; Magiera, D; Struharik, M; Ward, KW | 1 |
| Uzunović, A; Vranić, E | 1 |
| Allen, GP; Hankins, CD | 1 |
| Carmona, IT; Diz Dios, P; Limeres Posse, J; Núñez Otero, V | 1 |
| Chen, WL; Hu, FR; Tsai, TH | 1 |
| Heystek, M; Ross, JD | 1 |
| Davies, J; Mesak, LR | 1 |
| Carda-Broch, S; Esteve-Romero, J; Rambla-Alegre, M | 1 |
| Ardila, CM; Fernández, N; Guzmán, IC | 1 |
| Araújo, DP; de Almeida, MV; de Carvalho, GS; de Souza, MV; Saraiva, MF; Tran Huu Dau, ME | 1 |
| Bell, B; D'Arienzo, PA; Dajcs, JJ; Jamison, T; Stroman, DW; Wagner, RS | 1 |
| Chang, B; Knowles, SR; Weber, E | 1 |
| Clode, AB; Davis, JL; Gilger, BC; LaFevers, H; Salmon, J | 1 |
| Banaszkiewicz, A; Młynarczyk, G; Obuch-Woszczatyński, P; Pituch, H; Radzikowski, A; Wultańska, D | 1 |
| Baral, RM; Gottlieb, S; Govendir, M; Hansen, T; Kimble, B; Malik, R; Norris, JM; Wigney, DI | 1 |
| Hsueh, PR; Lee, PI; Yang, JC | 1 |
| Andreu, I; Aranda, A; Ariza, A; Blanca-Lopez, N; Doña, I; Mayorga, C; Rosado, A; Torres, MJ | 1 |
| Huang, FC; Shih, MH | 1 |
| Cox, SK; Hendrix, DV; Ward, DA; Westermeyer, HD | 1 |
| Acharya, NR; Cevallos, V; Fintelmann, RE; Gaynor, BD; Hoskins, EN; Keenan, JD; Lietman, TM | 1 |
| Gerding, DN; Johnson, S; Nagaro, K; Phillips, ST; Sambol, SP | 1 |
| Baik, GH; Jung, HC; Kim, GH; Kim, HB; Kim, JM; Kim, JY; Kim, NY; Kim, SJ; Lee, DH; Nam, RH; Song, IS | 1 |
| Biedenbach, DJ; Farrell, DJ; Jones, RN; Liverman, LC | 1 |
| Chamseddin, C; Jira, TH | 1 |
| Green, K; Low, DE; McGeer, A; Melano, R; Patel, SN; Pillai, DR; Tyrrell, GJ | 1 |
| Cremades, R; Galiana, A; García-Pachón, E; López, P; Rodríguez, JC; Royo, G; Ruiz-García, M | 1 |
| Lemaire, S; Marquez, B; Mingeot-Leclercq, MP; Ngabirano, E; Tulkens, PM; Vallet, CM; Van Bambeke, F | 1 |
| Anantharajah, A; Jacquet, E; Lallemand, JY; Marquez, B; Mingeot-Leclercq, MP; Nhiri, N; Tulkens, PM; Vallet, CM; Van Bambeke, F | 1 |
| Brown, DL; Drusano, GL; Heine, HS; Kulawy, RW; Louie, A; VanScoy, BD | 1 |
| Burd, EM; Sharp, SE | 1 |
| Galvis, V; Rey, JJ; Tello, A; Villareal, D; Wong, CA | 1 |
| Hooper, CY; Khan, A; Lightman, SL; Pacheco, P; Tam, PM; Taylor, SR | 1 |
| Chavda, K; Drlica, K; Hussain, S; Kerns, RJ; Kreiswirth, BN; Kurepina, N; Malik, M; Shah, N; Zhao, X | 1 |
| Malithong, A; Phiboonbanakit, D; Santiwatanakul, S; Srisangchan, P; Srisurat, N; Susaengrat, W; Tantisiriwat, W; Thamlikitkul, V; Thunyaharn, S; Tiengrim, S | 1 |
| Cvijovic, M; Di Marco, V; Djurdjevic, P; Stankov, MJ; Traldi, P | 1 |
| Albini, A; Fasani, E; Maraschi, F; Migliavacca, R; Nucleo, E; Pretali, L; Profumo, A; Speltini, A; Sturini, M | 1 |
| Fortier, LC; Meessen-Pinard, M; Sekulovic, O | 1 |
| Careño, E; Herreras, JM; Portero, A; Real, LA; Villarón, S | 1 |
| Andreu, I; Aranda, A; Ariza, A; Blanca, M; Blanca-Lopez, N; Doña, I; Mayorga, C; Miranda, MA; Montañez, MI; Nuin, E; Torres, MJ | 1 |
| Slavin, MA; Thursky, KA | 1 |
| Akan, H; Akova, M; Aoun, M; Calandra, T; de Bock, R; Drgona, L; Kern, WV; Marchetti, O; Paesmans, M; Viscoli, C | 1 |
| Bian, A; Blackman, A; Eden, S; Maruri, F; Mitchel, E; Shintani, AK; Sterling, TR; van der Heijden, YF; Warkentin, JV | 1 |
| Chang, CH; Chou, HW; Lai, MS; Lee, JJ; Shau, WY; Wang, JL | 1 |
| Budnitz, DS; Jones, SC; Mehta, H; Sorbello, A | 1 |
| Albini, A; Fasani, E; Maraschi, F; Pretali, L; Profumo, A; Speltini, A; Sturini, M | 1 |
| Jiang, B; Li, Y; Qiao, SS; Qu, Y; Wang, SH; Xie, YC; Xu, CL; Zhang, JY; Zhao, Y | 1 |
| Kalavathy, CM; Kaliamurthy, J; Nelson Jesudasan, CA; Parmar, P; Thomas, PA | 1 |
| Noreddin, AM; Salem, AH | 1 |
| Ghaly, H; Jörns, A; Rustenbeck, I | 1 |
| Alshammari, TM; Caffrey, AR; LaPlante, KL; Larrat, EP; Morrill, HJ; Quilliam, BJ | 1 |
| Grabowski, T; Grześkowiak, E; Karbownik, A; Sobańska, K; Szałek, E; Wolc, A | 1 |
| Al-Ahmad, A; Ameen, H; Anderson, AC; Hellwig, E; Karygianni, L; Pelz, K; Spitzmüller, B; Wittmer, A | 1 |
| Amorim, CL; Barreiro, JC; Cass, QB; Castro, PM; Maia, AS; Ribeiro, AR; Tiritan, ME | 1 |
| Demeestere, K; Dewulf, J; Haylamicheal, ID; Janssen, CR; Van Doorslaer, X; Van Langenhove, H | 1 |
| Brillault, J; Couet, W; Gobin, P; Gontijo, AV; Grégoire, N; Lamarche, I; Marchand, S | 1 |
| Djurdjevic, P; Ivanovic, N; Jakovljevic, I; Jelikic-Stankov, M; Joksovic, L | 1 |
| Aldred, KJ; Breland, EJ; Kerns, RJ; McPherson, SA; Osheroff, N; Turnbough, CL | 1 |
| Eshlaghi, SN; Vosough, M; Zadmard, R | 1 |
| Chan, KA; Chang, CH; Chou, HW; Lai, CL; Lai, MS; Wang, JL | 1 |
| Farhat, MR; Franke, MF; Jacobson, KR; Kaur, D; Mitnick, CD; Murray, M; Sloutsky, A | 1 |
| Kaur, S; Sharma, P | 1 |
| Bajgrowicz, M; Jones, L; Phan, CM; Subbaraman, LN | 1 |
| Lee, CH; Lee, LN; Lee, MC; Wang, JT; Wang, JY; Yu, MC | 1 |
| Buyck, JM; Peyrusson, F; Tulkens, PM; Van Bambeke, F | 1 |
| Gupta, K; Kumar, A; Rai, VK; Sabharwal, S; Shrivastava, R; Sinha, S; Tripathi, P | 1 |
| Saini, N; Sultana, S; Varshney, P; Yadav, J; Yadav, V | 1 |
| Cass, QB; Denadai, M | 1 |
| Beeton, ML; Chalker, VJ; Jones, LC; Maxwell, NC; Spiller, OB | 1 |
| Cataldi, V; Cellini, L; Ciccaglione, AF; Di Bartolomeo, S; Di Campli, E; Di Giulio, M; Grossi, L; Marzio, L; Nostro, A | 1 |
| Aldred, KJ; Berger, JM; Blower, TR; Kerns, RJ; Osheroff, N | 1 |
| Gent, JF; Holden, PN; Kong, Y; Murphy, TF; Pettigrew, MM; Sethi, S; Tsuji, BT | 1 |
| Grillon, A; Jehl, F; Kleinberg, M; Schramm, F | 1 |
| Chang, CM; Huang, CC; Ko, WC; Lee, CC; Lee, NY; Shih, HI; Tang, HJ; Wang, LR | 1 |
| Chaiprasert, A; Disratthakit, A; Doi, N; Leechawengwongs, M; Prammananan, T; Thaipisuttikul, I; Tribuddharat, C | 1 |
| Coan, EB; Miller, KE | 1 |
| Beberok, A; Buszman, E; Delijewski, M; Otręba, M; Respondek, M; Rok, J; Rzepka, Z; Wrześniok, D | 1 |
| Kriz, Z; Krutova, M; Kubicek, L; Kuijper, E; Matejkova, J; Nyc, O; Ruzicka, F; Tejkalova, R | 1 |
| Przybylski, DJ; Reeves, DJ | 1 |
| Bonato, PS; Faria-E-Sousa, SJ; Jabor, VAP; Martinez, EZ; Silva, GCM | 1 |
| Daoud, F; Kayser, O; Pelzer, D; Spiteller, M; Zuehlke, S | 1 |
| Clifton, DA; Crook, DW; Iqbal, Z; Niehaus, KE; Peto, TEA; Smith, EG; Walker, AS; Walker, TM; Wilson, DJ; Yang, Y; Zhu, T | 1 |
| El-Najjar, N; Gessner, A; Hösl, J | 1 |
| Aktoğu Özkan, S; Biçmen, C; Çavuşoğlu, C; Eraç, B; Ermertcan, Ş; Hoşgör Limoncu, M; Yılmaz, FF | 1 |
| Cho, Y; Park, HS | 1 |
| Chopra, V; Conlon, A; Flanders, SA; Gandhi, T; Malani, AN; Vaughn, VM | 1 |
| Huang, H; Huang, J; Jia, Y; Meng, L; Qiu, F; Sun, S | 1 |
| Kurz, X; McGettigan, P; Morales, D; Pacurariu, A; Pinheiro, L; Slattery, J | 1 |
| Ahmed, S; Al-Shaer, MH; Alghamdi, WA; Alkabab, Y; Alsultan, A; An, G; Banu, S; Barbakadze, K; Cegielski, JP; Heysell, SK; Houpt, E; Kempker, RR; Kipiani, M; Mikiashvili, L; Peloquin, CA | 1 |
| Chandrika, TN; Katta, KR; Mansoori, T; Reddy, AK; Srirampur, A | 1 |
| Aubry, A; Bleibtreu, A; Fourniols, E; Funck-Brentano, C; Jaureguiberry, S; LLopis, B; Tissot, N; Zahr, N | 1 |
| Galor, A; Huang, AM; Quan, AV | 1 |
| Cheng, JW; Fan, X; Hou, X; Kudinha, T; Liang, GW; Liu, C; Shao, DH; Su, JR; Wang, Y; Wei, M; Xiao, M; Xiong, ZJ; Xu, YC; Yang, CX; Yang, QW; Yu, SY | 1 |
| Bennett, AC; Bennett, CL; Witherspoon, BJ | 1 |
| Frassineti, GL; Monti, M; Ruscelli, S; Silimbani, P | 1 |
| Beberok, A; Boryczka, S; Marciniec, K; Pęcak, P; Wrześniok, D | 1 |
| Beare, PA; Bloom, ME; Broeckel, RM; Flather, DP; Kendall, BL; Morris, CN; Offerdahl, DK; Scroggs, SLP | 1 |
| Cabañas, R; Domínguez-Ortega, J; Fiandor, A; González-Muñoz, M; Lluch-Bernal, M; Loli-Ausejo, D; Vílchez-Sánchez, F | 1 |
| Brown Elliott, BA; Wallace, RJ | 1 |
| Azimi, A; Douraghi, M; Jafari, S; Rahbar, M; Rezaei, F; Yaseri, M | 1 |
| Bucsa, C; Farcas, A; Huruba, M; Leucuta, DC; Mogosan, C; Sipos, M | 1 |
| Allen, GP; Deao, KM; Hill, SA; Schipelliti, SM; Tran, T | 1 |
| Dogan, A; Donmez, F | 1 |
| Das, S; Gunasekaran, R; Mitra, S; Mohamed, A; Prajna, L; Prajna, NV; Sharma, S; Soni, T | 1 |
| Hand, RA; Henderson, A; Sullivan, MV; Turner, NW | 1 |
| Gao, Y; Ji, Y; Lin, Y; Lin, Z; Lu, Y; Yang, Y; Zhang, L | 1 |
| Alavi, A; Bayatloo, MR; Nojavan, S; Salehpour, N | 1 |
| Bykov, K; Fischer, MA; Gagne, JJ; Kattinakere-Sreedhara, S; Wang, J | 1 |
| Gunardi, WD; Moehario, LH; Nainggolan, IM; Nathania, I; Nusatia, ACM; Tjoa, E; Yasmon, A | 1 |
| Agrawal, D; Chatterjee, S; Gangwe, AB; Gomase, SN; Mishra, M; Parchand, SM | 1 |
| Berry, N; Byrne, DP; Fernig, DG; Foulkes, DM; Haneef, AS; Kaye, SB; McLean, K; Rustidge, S; Sloniecka, M; Winstanley, C | 1 |
| Chen, C; Cherian, P; Ebetino, FH; Hu, E; Junka, AF; McKenna, CE; Neighbors, J; Pawlak, J; Roshandel, S; Russell, RGG; Sedghizadeh, PP; Sodagar, E; Sun, S; Tjokro, N | 1 |
| Abou-Seri, SM; Elanany, MA; Gedawy, EM; Osman, EEA | 1 |
| Attin, T; Bensland, S; Eick, S; Karygianni, L; Kulik, EM; Thurnheer, T | 1 |
| Arslan, N; Esen, N; Özkarataş, MH; Özkütük, AA | 1 |
| Adams, KK; Clarke, LG; Shah, S | 1 |
| Algaidi, SH; Alghamdi, DI; Algheffari, SG; Alzahrani, RA; Hafiz, AM; Thabit, AK | 1 |
12 review(s) available for ciprofloxacin and moxifloxacin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Fluoroquinolone derivatives and their anti-tubercular activities.
Topics: Animals; Antitubercular Agents; Dose-Response Relationship, Drug; Fluoroquinolones; Humans; Molecular Structure; Mycobacterium tuberculosis; Structure-Activity Relationship; Tuberculosis | 2018 |
Fluoroquinolone-isatin hybrids and their biological activities.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antineoplastic Agents; Antitubercular Agents; Antiviral Agents; Fluoroquinolones; Humans; Isatin; Structure-Activity Relationship | 2019 |
Quinolone antibiotics.
Topics: | 2019 |
Moxifloxacin.
Topics: Anti-Infective Agents; Area Under Curve; Aza Compounds; Bacterial Infections; Ciprofloxacin; Drug Interactions; Fluoroquinolones; Half-Life; Humans; Metabolic Clearance Rate; Microbial Sensitivity Tests; Moxifloxacin; Quinolines | 1999 |
The role of fluoroquinolones in skin and skin structure infections.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Clinical Trials as Topic; Drug Resistance, Microbial; Enterococcus; Fluoroquinolones; Gram-Negative Bacteria; Humans; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Skin Diseases, Bacterial; Staphylococcus aureus; Streptococcus | 2002 |
Immunomodulatory effects of quinolones.
Topics: Adjuvants, Immunologic; Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Clinical Trials as Topic; Cytokines; Fluoroquinolones; Humans; Immune System; Models, Animal; Moxifloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolines | 2003 |
[Pathogenesis, diagnosis and therapy of Legionella infections].
Topics: Anti-Bacterial Agents; Antibodies, Bacterial; Antigens, Bacterial; Aza Compounds; Azithromycin; Ciprofloxacin; Diagnosis, Differential; DNA, Bacterial; Fluoroquinolones; Humans; Incidence; Legionella; Legionella pneumophila; Legionellosis; Legionnaires' Disease; Levofloxacin; Moxifloxacin; Ofloxacin; Polymerase Chain Reaction; Quinolines; Serotyping; Virulence | 2006 |
Dysglycemia and fluoroquinolones: are you putting patients at risk?
Topics: Adolescent; Adult; Aza Compounds; Bacterial Infections; Blood Glucose; Ciprofloxacin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Approval; Evidence-Based Medicine; Family Practice; Female; Fluoroquinolones; Gatifloxacin; Humans; Hyperglycemia; Hypoglycemia; Incidence; Male; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines; Randomized Controlled Trials as Topic; Risk Assessment; United States; United States Food and Drug Administration | 2007 |
Newest approaches to treatment of pelvic inflammatory disease: a review of recent randomized clinical trials.
Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Ciprofloxacin; Clindamycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Microbial; Female; Fluoroquinolones; Follow-Up Studies; Humans; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Pelvic Inflammatory Disease; Quinolines; Randomized Controlled Trials as Topic; Risk Assessment; Severity of Illness Index; Treatment Outcome | 2007 |
Interactions between warfarin and three commonly prescribed fluoroquinolones.
Topics: Aza Compounds; Ciprofloxacin; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Fluoroquinolones; Humans; International Normalized Ratio; Levofloxacin; Moxifloxacin; Ofloxacin; Quinolines; Warfarin | 2008 |
Efficacy of fluoroquinolones against pathogenic oral bacteria.
Topics: Aza Compounds; Bacteria; Bacterial Infections; Ciprofloxacin; Fluoroquinolones; Humans; Levofloxacin; Mouth Diseases; Moxifloxacin; Ofloxacin; Oral Medicine; Quinolines | 2009 |
7 trial(s) available for ciprofloxacin and moxifloxacin
| Article | Year |
|---|---|
Human aqueous humor levels of oral ciprofloxacin, levofloxacin, and moxifloxacin.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anti-Infective Agents; Aqueous Humor; Aza Compounds; Biological Availability; Cataract Extraction; Ciprofloxacin; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Ofloxacin; Prospective Studies; Quinolines; Tissue Distribution | 2001 |
Effects of three fluoroquinolones on QT interval in healthy adults after single doses.
Topics: Adult; Aged; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Fluoroquinolones; Heart Rate; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines | 2003 |
Penetration of topically applied gatifloxacin 0.3%, moxifloxacin 0.5%, and ciprofloxacin 0.3% into the aqueous humor.
Topics: Aged; Anti-Infective Agents; Aqueous Humor; Aza Compounds; Biological Availability; Cataract Extraction; Chromatography, High Pressure Liquid; Ciprofloxacin; Double-Blind Method; Female; Fluoroquinolones; Gatifloxacin; Humans; Male; Middle Aged; Moxifloxacin; Ophthalmic Solutions; Prospective Studies; Quinolines | 2005 |
Effects of three fluoroquinolones on QT analysis after standard treatment courses.
Topics: Analysis of Variance; Aza Compounds; Ciprofloxacin; Cross-Over Studies; Electrocardiography; Female; Fluoroquinolones; Heart Rate; Humans; Levofloxacin; Long QT Syndrome; Male; Moxifloxacin; Ofloxacin; Quinolines; Statistics, Nonparametric; Torsades de Pointes | 2006 |
A randomized double-blind comparison of moxifloxacin and doxycycline/metronidazole/ciprofloxacin in the treatment of acute, uncomplicated pelvic inflammatory disease.
Topics: Acute Disease; Adult; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Double-Blind Method; Doxycycline; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Metronidazole; Moxifloxacin; Pelvic Inflammatory Disease; Quinolines; Treatment Outcome | 2009 |
In vitro evaluation of IgE-mediated hypersensitivity reactions to quinolones.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Aza Compounds; Basophil Degranulation Test; Ciprofloxacin; Female; Fluoroquinolones; Humans; Hypersensitivity, Immediate; Immunologic Tests; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines; Quinolones; Radioimmunoassay; Sensitivity and Specificity; Young Adult | 2011 |
Oral antibiotics for fever in low-risk neutropenic patients with cancer: a double-blind, randomized, multicenter trial comparing single daily moxifloxacin with twice daily ciprofloxacin plus amoxicillin/clavulanic acid combination therapy--EORTC infectiou
Topics: Administration, Oral; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Clavulanic Acid; Double-Blind Method; Drug Combinations; Female; Fever; Fluoroquinolones; Humans; Injections, Intravenous; Male; Middle Aged; Moxifloxacin; Neoplasms; Neutropenia; Quinolines; Risk Factors; Treatment Outcome | 2013 |
371 other study(ies) available for ciprofloxacin and moxifloxacin
| Article | Year |
|---|---|
Synthesis and structure-activity relationships of 5-amino-6-fluoro-1-[(1R,2S)-2-fluorocyclopropan-1-yl]-8-methylquinolonecarboxylic acid antibacterials having fluorinated 7-[(3R)-3-(1-aminocyclopropan-1-yl)pyrrolidin-1-yl] substituents.
Topics: Anti-Bacterial Agents; Cyclopropanes; Drug Resistance, Bacterial; Gram-Positive Bacteria; Microbial Sensitivity Tests; Quinolones; Stereoisomerism; Structure-Activity Relationship | 2003 |
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
Inhibitors of multidrug resistance (MDR) have affinity for MDR substrates.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Biological Transport; Cell Membrane; Drug Resistance, Microbial; Drug Resistance, Multiple; Ligands; Models, Molecular | 2004 |
Chemometric studies on the bactericidal activity of quinolones via an extended VolSurf approach.
Topics: Anti-Bacterial Agents; Enterococcus faecalis; Escherichia coli; Models, Molecular; Pseudomonas aeruginosa; Quantitative Structure-Activity Relationship; Quinolones; Staphylococcus aureus; Thermodynamics | 2004 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
Topics: Algorithms; Animals; Dogs; Haplorhini; Humans; Pharmaceutical Preparations; Pharmacokinetics; Rats; Species Specificity; Tissue Distribution | 2005 |
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
Topics: Administration, Oral; Animals; Area Under Curve; Dogs; Haplorhini; Humans; Models, Statistical; Rats; Software; Species Specificity; Xenobiotics | 2005 |
A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
Topics: Animals; Anti-Bacterial Agents; Area Under Curve; Clinical Trials, Phase I as Topic; Dogs; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolones; Half-Life; Humans; Infusions, Intravenous; Injections, Intravenous; Male; Methicillin Resistance; Mice; Microbial Sensitivity Tests; Mutation; Prodrugs; Quinolizines; Rats; Rats, Wistar; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Structure-Activity Relationship; Vancomycin Resistance | 2005 |
Biological evaluation of isothiazoloquinolones containing aromatic heterocycles at the 7-position: In vitro activity of a series of potent antibacterial agents that are effective against methicillin-resistant Staphylococcus aureus.
Topics: Anti-Bacterial Agents; Azo Compounds; Cell Line, Tumor; Cyclization; Fluorine; Humans; Methicillin Resistance; Molecular Structure; Quinolones; Staphylococcus aureus; Structure-Activity Relationship; Sulfhydryl Compounds | 2006 |
Isothiazoloquinolones containing functionalized aromatic hydrocarbons at the 7-position: synthesis and in vitro activity of a series of potent antibacterial agents with diminished cytotoxicity in human cells.
Topics: Anti-Bacterial Agents; Azo Compounds; Cell Line; Escherichia coli; Humans; Hydrocarbons, Aromatic; Microbial Sensitivity Tests; Molecular Structure; Quinolines; Staphylococcus aureus; Sulfhydryl Compounds | 2006 |
Association of QnrB determinants and production of extended-spectrum beta-lactamases or plasmid-mediated AmpC beta-lactamases in clinical isolates of Klebsiella pneumoniae.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Cephalosporins; Drug Resistance, Multiple, Bacterial; Escherichia coli; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Plasmids; Quinolones | 2007 |
Influence on mitochondria and cytotoxicity of different antibiotics administered in high concentrations on primary human osteoblasts and cell lines.
Topics: Acetamides; Aminoglycosides; Anti-Bacterial Agents; Antimycin A; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cells, Cultured; Chloramphenicol; Clindamycin; Dose-Response Relationship, Drug; Fluoroquinolones; Glycolysis; HeLa Cells; Humans; Lactic Acid; Linezolid; Macrolides; Mitochondria; Osteoblasts; Oxazolidinones; Rotenone; Tetracyclines; Time Factors | 2007 |
Synthesis of omeprazole analogues and evaluation of these as potential inhibitors of the multidrug efflux pump NorA of Staphylococcus aureus.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Culture Media; Drug Resistance, Multiple, Bacterial; Enzyme Inhibitors; Indicators and Reagents; Kinetics; Microbial Sensitivity Tests; Multidrug Resistance-Associated Proteins; Norfloxacin; Omeprazole; Staphylococcus aureus; Structure-Activity Relationship | 2007 |
Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae.
Topics: DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Mutation; Pneumococcal Infections; Streptococcus pneumoniae; Transformation, Bacterial | 2007 |
Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy.
Topics: Animals; Anti-Bacterial Agents; Antitubercular Agents; Aza Compounds; Ciprofloxacin; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Fluoroquinolones; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Predictive Value of Tests; Quinolines; Time Factors; Tuberculosis | 2007 |
Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
Topics: Anti-Bacterial Agents; Antitubercular Agents; DNA, Bacterial; Drug Evaluation, Preclinical; Mycobacterium tuberculosis; Oxygen | 2007 |
In vitro studies with DQ-113 and comparison fluoroquinolones to determine propensities to select resistance in gram-positive cocci.
Topics: Drug Resistance, Bacterial; Drug Resistance, Microbial; Fluoroquinolones; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Microbial Sensitivity Tests; Quinolones | 2007 |
Isothiazoloquinolones with enhanced antistaphylococcal activities against multidrug-resistant strains: effects of structural modifications at the 6-, 7-, and 8-positions.
Topics: Animals; Anti-Bacterial Agents; Cell Line, Tumor; Drug Resistance, Multiple, Bacterial; Female; Humans; Methicillin Resistance; Mice; Quinolones; Staphylococcus aureus; Structure-Activity Relationship; Thiazoles; Topoisomerase II Inhibitors | 2007 |
In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.
Topics: Animals; Anti-Infective Agents; Drug Resistance, Bacterial; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Mice; Microbial Sensitivity Tests; Quinolones; Thiazoles | 2007 |
Fluoroquinolone resistance in Haemophilus influenzae is associated with hypermutability.
Topics: Anti-Infective Agents; Drug Resistance, Bacterial; Fluoroquinolones; Genes, Bacterial; Haemophilus Infections; Haemophilus influenzae; Humans; Microbial Sensitivity Tests; Mutation | 2007 |
Expression and purification of an active form of the Mycobacterium leprae DNA gyrase and its inhibition by quinolones.
Topics: Anti-Infective Agents; DNA; DNA Gyrase; DNA, Superhelical; Enzyme Inhibitors; Mycobacterium leprae; Quinolones; Topoisomerase II Inhibitors | 2007 |
Mutant prevention concentrations of fluoroquinolones for Enterobacteriaceae expressing the plasmid-carried quinolone resistance determinant qnrA1.
Topics: Anti-Infective Agents; Bacterial Proteins; Colony Count, Microbial; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Enterobacteriaceae; Escherichia coli Proteins; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Mutation; Plasmids | 2007 |
Vibrio splendidus as the source of plasmid-mediated QnrS-like quinolone resistance determinants.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Proteins; Computer Simulation; DNA, Bacterial; Drug Resistance, Bacterial; Escherichia coli; Genes, Bacterial; Microbial Sensitivity Tests; Molecular Sequence Data; Nucleic Acid Amplification Techniques; Open Reading Frames; Plasmids; Polymerase Chain Reaction; Quinolones; Sequence Analysis, DNA; Sequence Homology, Amino Acid; Vibrio | 2007 |
Transferable resistance to aminoglycosides by methylation of G1405 in 16S rRNA and to hydrophilic fluoroquinolones by QepA-mediated efflux in Escherichia coli.
Topics: Amino Acid Motifs; Amino Acid Sequence; Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; Conjugation, Genetic; Conserved Sequence; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Escherichia coli; Escherichia coli Proteins; Fluoroquinolones; Genes, rRNA; Methylation; Methyltransferases; Microbial Sensitivity Tests; Molecular Sequence Data; Norfloxacin; Plasmids; Sequence Analysis, DNA; Sequence Homology, Amino Acid | 2007 |
Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.
Topics: Anti-Bacterial Agents; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Microbial Sensitivity Tests; Molecular Structure; Mutation; Quinolones; Staphylococcus aureus; Thiazoles; Topoisomerase II Inhibitors | 2007 |
Plasmid-mediated quinolone resistance determinant QnrB4 identified in France in an Enterobacter cloacae clinical isolate coexpressing a QnrS1 determinant.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Child, Preschool; Conjugation, Genetic; Drug Resistance, Bacterial; Enterobacter cloacae; Escherichia coli; France; Genes, Bacterial; Humans; Microbial Sensitivity Tests; Plasmids; Quinolones; Transformation, Genetic | 2007 |
New plasmid-mediated fluoroquinolone efflux pump, QepA, found in an Escherichia coli clinical isolate.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Chitosan; Conjugation, Genetic; DNA, Bacterial; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Fluoroquinolones; Humans; Malates; Microbial Sensitivity Tests; Molecular Sequence Data; Plasmids; Reverse Transcriptase Polymerase Chain Reaction; Transformation, Bacterial; Uncoupling Agents | 2007 |
Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.
Topics: Anaerobiosis; Animals; Anti-Infective Agents; Bacterial Toxins; Cecum; Clostridioides difficile; Disease Models, Animal; Disease Outbreaks; Drug Resistance, Bacterial; Enterocolitis, Pseudomembranous; Fluoroquinolones; Humans; Mice; Microbial Sensitivity Tests | 2007 |
Role of a qnr-like gene in the intrinsic resistance of Enterococcus faecalis to fluoroquinolones.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Proteins; Culture Media; DNA Gyrase; Drug Resistance, Bacterial; Enterococcus faecalis; Fluoroquinolones; Gene Expression Regulation, Bacterial; Genes, Bacterial; Microbial Sensitivity Tests; Molecular Sequence Data; Reverse Transcriptase Polymerase Chain Reaction | 2007 |
Contributions of the combined effects of topoisomerase mutations toward fluoroquinolone resistance in Escherichia coli.
Topics: DNA Topoisomerases; Drug Resistance, Bacterial; Escherichia coli; Fluoroquinolones; Microbial Sensitivity Tests; Mutation | 2007 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Antimicrobial susceptibilities and clinical sources of Dialister species.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Species Specificity; Veillonellaceae | 2007 |
Complex class 1 integrons with diverse variable regions, including aac(6')-Ib-cr, and a novel allele, qnrB10, associated with ISCR1 in clinical enterobacterial isolates from Argentina.
Topics: Alleles; Amino Acid Sequence; Argentina; Bacterial Proteins; Base Sequence; beta-Lactamases; Cross Infection; DNA Transposable Elements; Drug Resistance, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Integrons; Microbial Sensitivity Tests; Molecular Sequence Data; Polymerase Chain Reaction; Sequence Analysis, DNA; Sequence Homology, Nucleic Acid | 2007 |
In vitro activity of DC-159a, a new broad-spectrum fluoroquinolone, compared with that of other agents against drug-susceptible and -resistant pneumococci.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Culture Media; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Mutation; Streptococcus pneumoniae | 2008 |
Evaluation of a 2-pyridone, KRQ-10018, against Mycobacterium tuberculosis in vitro and in vivo.
Topics: Animals; Antitubercular Agents; Biological Availability; Interferon-gamma; Mice; Mice, Inbred C57BL; Mice, Knockout; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Pyridones; Quinolones; Treatment Outcome; Tuberculosis, Pulmonary | 2008 |
Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; beta-Lactamases; Canada; Drug Resistance, Bacterial; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Intensive Care Units; Male; Microbial Sensitivity Tests; Middle Aged; Population Surveillance | 2008 |
Emergence of fluoroquinolone resistance in group B streptococcal isolates in Taiwan.
Topics: Bacterial Proteins; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Mutation; Ofloxacin; Streptococcus agalactiae; Taiwan | 2008 |
Comparison of the in vitro efficacies of moxifloxacin and amoxicillin against Listeria monocytogenes.
Topics: Amoxicillin; Animals; Aza Compounds; Cells, Cultured; Fluoroquinolones; Listeria monocytogenes; Macrophages; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Moxifloxacin; Quinolines | 2008 |
Antimicrobial susceptibilities of geographically diverse clinical human isolates of Leptospira.
Topics: Ampicillin; Anti-Bacterial Agents; Azithromycin; Cefepime; Cefotaxime; Ceftriaxone; Cephalosporins; Ciprofloxacin; Egypt; Hawaii; Humans; Leptospira; Leptospirosis; Levofloxacin; Microbial Sensitivity Tests; Nicaragua; Ofloxacin; Tetracycline; Thailand | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
Plasmid-mediated quinolone resistance pump QepA2 in an Escherichia coli isolate from France.
Topics: Aged; Base Sequence; DNA Primers; DNA, Bacterial; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Female; Fluoroquinolones; France; Genes, Bacterial; Humans; Models, Genetic; Molecular Sequence Data; Plasmids | 2008 |
Smqnr, a new chromosome-carried quinolone resistance gene in Stenotrophomonas maltophilia.
Topics: Alleles; Amino Acid Sequence; Anti-Bacterial Agents; Base Sequence; Chromosomes, Bacterial; DNA Primers; DNA, Bacterial; Drug Resistance, Bacterial; Fluoroquinolones; Genes, Bacterial; Gram-Negative Bacterial Infections; Humans; Molecular Sequence Data; Sequence Homology, Amino Acid; Stenotrophomonas maltophilia | 2008 |
Comparative in vitro activities of the investigational fluoroquinolone DC-159a and other antimicrobial agents against human mycoplasmas and ureaplasmas.
Topics: Aminopyridines; Anti-Bacterial Agents; Fluoroquinolones; Humans; In Vitro Techniques; Microbial Sensitivity Tests; Mycoplasma; Mycoplasma fermentans; Mycoplasma genitalium; Mycoplasma hominis; Mycoplasma Infections; Mycoplasma pneumoniae; Ureaplasma; Ureaplasma Infections | 2008 |
Effects of exposure of Clostridium difficile PCR ribotypes 027 and 001 to fluoroquinolones in a human gut model.
Topics: Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Clostridioides difficile; Colony Count, Microbial; Cytotoxins; DNA Gyrase; Feces; Fluoroquinolones; Gastrointestinal Tract; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Reverse Transcriptase Polymerase Chain Reaction; Ribotyping | 2009 |
Effect of electrical current on the activities of antimicrobial agents against Pseudomonas aeruginosa, Staphylococcus aureus, and Staphylococcus epidermidis biofilms.
Topics: Anti-Infective Agents; Biofilms; Bioreactors; Electricity; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Staphylococcus aureus; Staphylococcus epidermidis | 2009 |
Real-time PCR detection of gyrA and parC mutations in Streptococcus pneumoniae.
Topics: Amino Acid Substitution; Base Sequence; DNA Gyrase; DNA Mutational Analysis; DNA Primers; DNA Probes; DNA Topoisomerase IV; DNA, Bacterial; Drug Resistance, Bacterial; Fluoroquinolones; Genes, Bacterial; Humans; Nucleic Acid Denaturation; Point Mutation; Polymerase Chain Reaction; Streptococcus pneumoniae; Thermodynamics | 2008 |
Use of gyrase resistance mutants to guide selection of 8-methoxy-quinazoline-2,4-diones.
Topics: Anti-Bacterial Agents; DNA Gyrase; Drug Resistance, Bacterial; Escherichia coli; Fluoroquinolones; Genes, Bacterial; Humans; Mutation; Quinazolinones; Structure-Activity Relationship | 2008 |
Bisphosphonated fluoroquinolone esters as osteotropic prodrugs for the prevention of osteomyelitis.
Topics: Animals; Disease Models, Animal; Esters; Female; Fluoroquinolones; Humans; Molecular Structure; Organophosphonates; Osteomyelitis; Prodrugs; Rats | 2008 |
Linking bisphosphonates to the free amino groups in fluoroquinolones: preparation of osteotropic prodrugs for the prevention of osteomyelitis.
Topics: Amines; Animals; Cell Line; Diphosphonates; Female; Fluoroquinolones; Molecular Structure; Osteomyelitis; Prodrugs; Rats; Structure-Activity Relationship | 2008 |
Efficacy of ciprofloxacin and moxifloxacin against Nocardia brasiliensis in vitro and in an experimental model of actinomycetoma in BALB/c mice.
Topics: Animals; Aza Compounds; Ciprofloxacin; Disease Models, Animal; Female; Fluoroquinolones; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Moxifloxacin; Mycetoma; Nocardia; Quinolines | 2009 |
Antimicrobial susceptibility of Mycoplasma pneumoniae isolates and molecular analysis of macrolide-resistant strains from Shanghai, China.
Topics: Adhesins, Bacterial; Anti-Bacterial Agents; Child; China; Drug Resistance, Bacterial; Genes, rRNA; Humans; Macrolides; Microbial Sensitivity Tests; Mutation; Mycoplasma pneumoniae; Pneumonia, Mycoplasma; Polymerase Chain Reaction; Polymorphism, Restriction Fragment Length; Respiratory Tract Infections; RNA, Ribosomal, 23S; Sequence Analysis, DNA | 2009 |
Prevalence of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme among Enterobacteriaceae blood isolates in Korea.
Topics: Acetyltransferases; beta-Lactamases; Ciprofloxacin; Conjugation, Genetic; Enterobacteriaceae; Microbial Sensitivity Tests; Plasmids | 2009 |
Comparative antipneumococcal activities of sulopenem and other drugs.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Lactams; Microbial Sensitivity Tests; Penicillin-Binding Proteins; Streptococcus pneumoniae | 2009 |
Antimicrobial ambiguine isonitriles from the cyanobacterium Fischerella ambigua.
Topics: Anti-Bacterial Agents; Bacillus anthracis; Cyanobacteria; Indole Alkaloids; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Nuclear Magnetic Resonance, Biomolecular | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
In vitro activity of garenoxacin against Streptococcus pneumoniae mutants with characterized resistance mechanisms.
Topics: Anti-Bacterial Agents; DNA Gyrase; DNA Topoisomerases; Drug Resistance, Bacterial; Fluoroquinolones; Microbial Sensitivity Tests; Mutation; Streptococcus pneumoniae | 2009 |
Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria.
Topics: Anti-Bacterial Agents; Azepines; Bacteria, Anaerobic; Drug Resistance, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests | 2009 |
Characterization of the plasmid-borne quinolone resistance gene qnrB19 in Salmonella enterica serovar Typhimurium.
Topics: Anti-Bacterial Agents; Bacterial Proteins; DNA Transposable Elements; Drug Resistance, Multiple, Bacterial; Evolution, Molecular; Microbial Sensitivity Tests; Multigene Family; Plasmids; Quinolones; Salmonella typhimurium | 2009 |
7-((4-Substituted)piperazin-1-yl) derivatives of ciprofloxacin: synthesis and in vitro biological evaluation as potential antitumor agents.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Ciprofloxacin; Humans; Maximum Tolerated Dose; Mice; Neoplasms; Piperazine; Piperazines | 2009 |
Mechanisms of resistance in nontyphoidal Salmonella enterica strains exhibiting a nonclassical quinolone resistance phenotype.
Topics: Bacterial Proteins; Drug Resistance, Bacterial; Electroporation; Genotype; Microbial Sensitivity Tests; Plasmids; Polymerase Chain Reaction; Quinolones; Salmonella enterica | 2009 |
Design, synthesis and biological evaluations of novel 7-[3-(1-aminocycloalkyl)pyrrolidin-1-yl]-6-desfluoro-8-methoxyquinolones with potent antibacterial activity against multi-drug resistant Gram-positive bacteria.
Topics: Anti-Bacterial Agents; Drug Design; Drug Resistance, Multiple; Gram-Positive Bacteria; Microbial Sensitivity Tests; Quinolones; Structure-Activity Relationship | 2009 |
In vitro activity of a new quinoline derivative, ER-2, against clinical isolates of Mycoplasma pneumoniae and Mycoplasma hominis.
Topics: Anti-Bacterial Agents; Humans; Microbial Sensitivity Tests; Molecular Structure; Mycoplasma hominis; Mycoplasma pneumoniae; Pneumonia, Mycoplasma; Quinolines | 2009 |
In vitro activity of nemonoxacin, a novel nonfluorinated quinolone, against 2,440 clinical isolates.
Topics: Anti-Infective Agents; Bacteria; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Quinolones | 2009 |
Antimicrobial susceptibilities of Mycoplasma genitalium strains examined by broth dilution and quantitative PCR.
Topics: Microbial Sensitivity Tests; Mycoplasma genitalium; Polymerase Chain Reaction | 2009 |
Prevalence and clonal characterization of Streptococcus pyogenes clinical isolates with reduced fluoroquinolone susceptibility in Spain.
Topics: Adult; Anti-Bacterial Agents; Child; Drug Resistance, Bacterial; Female; Fluoroquinolones; Genes, Bacterial; Humans; Male; Microbial Sensitivity Tests; Mutation; Prospective Studies; Spain; Streptococcal Infections; Streptococcus pyogenes | 2010 |
Relative contributions of active mediated transport and passive diffusion of fluoroquinolones with various lipophilicities in a Calu-3 lung epithelial cell model.
Topics: Absorption; Anti-Bacterial Agents; ATP Binding Cassette Transporter, Subfamily B; Biological Transport, Active; Cell Line; Cell Membrane Permeability; Cyclosporins; Diffusion; Drug Interactions; Drug Resistance, Bacterial; Epithelial Cells; Fluoroquinolones; Kinetics; Lipids; Lung | 2010 |
SmQnr contributes to intrinsic resistance to quinolones in Stenotrophomonas maltophilia.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Gene Expression Regulation, Bacterial; Microbial Sensitivity Tests; Mutation; Plasmids; Quinolones; Reverse Transcriptase Polymerase Chain Reaction; Stenotrophomonas maltophilia | 2010 |
Enhancement of the antimalarial activity of ciprofloxacin using a double prodrug/bioorganometallic approach.
Topics: Aminoquinolines; Antimalarials; Ciprofloxacin; Ferrous Compounds; Metallocenes; Plasmodium falciparum; Prodrugs | 2009 |
Comparative study of the mutant prevention concentrations of moxifloxacin, levofloxacin, and gemifloxacin against pneumococci.
Topics: Anti-Bacterial Agents; Aza Compounds; DNA Topoisomerases, Type II; Drug Resistance, Bacterial; Fluoroquinolones; Gemifloxacin; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Naphthyridines; Ofloxacin; Polymerase Chain Reaction; Quinolines; Streptococcus pneumoniae | 2010 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Antimicrobial susceptibilities of multidrug-resistant Campylobacter jejuni and C. coli strains: in vitro activities of 20 antimicrobial agents.
Topics: Anti-Bacterial Agents; Campylobacter coli; Campylobacter Infections; Campylobacter jejuni; Carbapenems; Drug Resistance, Multiple, Bacterial; Erythromycin; Feces; Finland; Humans; Macrolides; Microbial Sensitivity Tests; Minocycline; Tigecycline | 2010 |
Comparative in vitro activities of nemonoxacin (TG-873870), a novel nonfluorinated quinolone, and other quinolones against clinical isolates.
Topics: Anti-Bacterial Agents; Aza Compounds; Drug Resistance, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Cocci; Humans; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Quinolones; Taiwan | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
In vitro antibacterial activities of JNJ-Q2, a new broad-spectrum fluoroquinolone.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Design; Drug Resistance, Bacterial; Escherichia coli; Fluoroquinolones; Methicillin-Resistant Staphylococcus aureus; Streptococcus pneumoniae | 2010 |
Emergence of ciprofloxacin-nonsusceptible Streptococcus pyogenes isolates from healthy children and pediatric patients in Portugal.
Topics: Amino Acid Substitution; Anti-Bacterial Agents; Antigens, Bacterial; Bacterial Outer Membrane Proteins; Bacterial Typing Techniques; Carrier Proteins; Child; Ciprofloxacin; Drug Resistance, Bacterial; Humans; Molecular Epidemiology; Norfloxacin; Point Mutation; Portugal; Streptococcal Infections; Streptococcus pyogenes | 2010 |
In vitro activity of the aminoglycoside antibiotic arbekacin against Acinetobacter baumannii-calcoaceticus isolated from war-wounded patients at Walter Reed Army Medical Center.
Topics: Acinetobacter baumannii; Aminoglycosides; Anti-Bacterial Agents; Carbapenems; Dibekacin; Hospitals, Military; Humans; Microbial Sensitivity Tests; Warfare | 2010 |
From 6-aminoquinolone antibacterials to 6-amino-7-thiopyranopyridinylquinolone ethyl esters as inhibitors of Staphylococcus aureus multidrug efflux pumps.
Topics: Aminoquinolines; Anti-Bacterial Agents; Drug Resistance, Multiple; Esters; Ethidium; Genes, MDR; Microbial Sensitivity Tests; Staphylococcus aureus; Structure-Activity Relationship | 2010 |
Synthesis and biological evaluation of tetracyclic fluoroquinolones as antibacterial and anticancer agents.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Line; Cell Line, Tumor; DNA Gyrase; DNA Topoisomerase IV; Escherichia coli; Escherichia coli Infections; Female; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Topoisomerase II Inhibitors | 2010 |
In vitro and in vivo activities of LCB01-0371, a new oxazolidinone.
Topics: Acetamides; Animals; Anti-Bacterial Agents; Bacterial Infections; Gram-Positive Bacteria; Linezolid; Male; Mice; Mice, Inbred ICR; Oxazolidinones; Staphylococcus aureus; Vancomycin | 2010 |
In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient.
Topics: Acinetobacter baumannii; Acinetobacter Infections; Bacterial Proteins; Carbapenems; Drug Resistance, Bacterial; Fatal Outcome; Humans; Male; Middle Aged; Molecular Sequence Data; Mutation, Missense; Reverse Transcriptase Polymerase Chain Reaction | 2010 |
In vitro effect of qnrA1, qnrB1, and qnrS1 genes on fluoroquinolone activity against isogenic Escherichia coli isolates with mutations in gyrA and parC.
Topics: Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Escherichia coli; Escherichia coli Proteins; Fluoroquinolones; Microbial Sensitivity Tests; Mutation | 2011 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
Exploration of the activity of 7-pyrrolidino-8-methoxyisothiazoloquinolones against methicillin-resistant Staphylococcus aureus (MRSA).
Topics: Anti-Bacterial Agents; DNA Topoisomerase IV; Drug Resistance, Multiple, Bacterial; Escherichia coli; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Pyrrolidines; Quinolones; Stereoisomerism; Structure-Activity Relationship; Thiazoles; Topoisomerase II Inhibitors | 2011 |
Selenophene-containing inhibitors of type IIA bacterial topoisomerases.
Topics: Anti-Bacterial Agents; Cell Line, Tumor; DNA Topoisomerase IV; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Methicillin-Resistant Staphylococcus aureus; Organoselenium Compounds; Piperidines; Quinolines; Staphylococcus aureus; Stereoisomerism; Structure-Activity Relationship; Thiophenes; Topoisomerase II Inhibitors | 2011 |
Synthesis and biological evaluation of tetracyclic thienopyridones as antibacterial and antitumor agents.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Dose-Response Relationship, Drug; Female; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Thienopyridines; Topoisomerase II Inhibitors | 2011 |
Synthesis and evaluation of 1-cyclopropyl-2-thioalkyl-8-methoxy fluoroquinolones.
Topics: Anti-Infective Agents; Aza Compounds; DNA Gyrase; Fluoroquinolones; Microbial Sensitivity Tests; Moxifloxacin; Protein Binding; Quinolines; Topoisomerase II Inhibitors | 2011 |
Synthesis and antibacterial activity of naphthyridone derivatives containing mono/difluoro-methyloxime pyrrolidine scaffolds.
Topics: Animals; Anti-Bacterial Agents; Bacteria; Male; Mice; Naphthyridines; Oximes; Pyrrolidines | 2012 |
Synthesis, antitubercular and antimicrobial evaluation of 3-(4-chlorophenyl)-4-substituted pyrazole derivatives.
Topics: Anti-Infective Agents; Antitubercular Agents; Fungi; Gram-Negative Bacteria; Gram-Positive Bacteria; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Pyrazoles; Structure-Activity Relationship | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Synthesis of gatifloxacin derivatives and their biological activities against Mycobacterium leprae and Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Aza Compounds; DNA Cleavage; DNA Gyrase; Fluoroquinolones; Gatifloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium leprae; Mycobacterium tuberculosis; Quinolines; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2013 |
Design, synthesis, and biological evaluations of novel 7-[7-amino-7-methyl-5-azaspiro[2.4]heptan-5-yl]-8-methoxyquinolines with potent antibacterial activity against respiratory pathogens.
Topics: Animals; Anti-Bacterial Agents; Drug Design; Fluoroquinolones; Haemophilus influenzae; Male; Mice; Microbial Sensitivity Tests; Quinolones; Rats; Respiratory Tract Infections; Spiro Compounds; Staphylococcus aureus; Streptococcus pneumoniae | 2013 |
The synergic modeling for the binding of fluoroquinolone antibiotics to the hERG potassium channel.
Topics: Anti-Bacterial Agents; Binding Sites; Dose-Response Relationship, Drug; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Fluoroquinolones; Humans; Models, Molecular; Potassium Channel Blockers; Structure-Activity Relationship | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Design, synthesis, and biological evaluation of dihydroartemisinin-fluoroquinolone conjugates as a novel type of potential antitubercular agents.
Topics: Antitubercular Agents; Artemisinins; Drug Design; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Structure-Activity Relationship | 2014 |
Novel N-linked aminopiperidine-based gyrase inhibitors with improved hERG and in vivo efficacy against Mycobacterium tuberculosis.
Topics: Acute Disease; Administration, Oral; Animals; Antitubercular Agents; Bacterial Proteins; Biological Availability; Chronic Disease; DNA Gyrase; Drug Resistance, Bacterial; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Fluoroquinolones; Humans; Macrophages; Mice, Inbred BALB C; Microbial Sensitivity Tests; Molecular Docking Simulation; Mutation; Mycobacterium tuberculosis; Piperidines; Protein Subunits; Rats; Stereoisomerism; Structure-Activity Relationship; Topoisomerase II Inhibitors; Tuberculosis, Pulmonary | 2014 |
Benzimidazoles: novel mycobacterial gyrase inhibitors from scaffold morphing.
Topics: | 2014 |
Synthesis, antimycobacterial and antibacterial evaluation of l-[(1R, 2S)-2-fluorocyclopropyl]fluoroquinolone derivatives containing an oxime functional moiety.
Topics: Anti-Bacterial Agents; Bacteria; Dose-Response Relationship, Drug; Fluoroquinolones; Microbial Sensitivity Tests; Molecular Structure; Oximes; Structure-Activity Relationship | 2014 |
Left-Hand Side Exploration of Novel Bacterial Topoisomerase Inhibitors to Improve Selectivity against hERG Binding.
Topics: | 2015 |
Synthesis and biological evaluation of levofloxacin core-based derivatives with potent antibacterial activity against resistant Gram-positive pathogens.
Topics: Anti-Bacterial Agents; Dose-Response Relationship, Drug; Levofloxacin; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Molecular Structure; Penicillin Resistance; Streptococcus pneumoniae; Streptococcus pyogenes; Structure-Activity Relationship | 2015 |
Synthesis, antimycobacterial and antibacterial activity of l-[(1R,2S)-2-fluorocyclopropyl]naphthyridone derivatives containing an oxime-functionalized pyrrolidine moiety.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Levofloxacin; Moxifloxacin; Naphthyridines; Oximes; Pyrrolidines; Stereoisomerism | 2015 |
Synthesis, antimycobacterial and antibacterial activity of 1-(6-amino-3,5-difluoropyridin-2-yl)fluoroquinolone derivatives containing an oxime functional moiety.
Topics: Anti-Bacterial Agents; Antitubercular Agents; Fluoroquinolones; Oximes | 2016 |
Metabolites from the Fungal Endophyte Aspergillus austroafricanus in Axenic Culture and in Fungal-Bacterial Mixed Cultures.
Topics: Animals; Anti-Bacterial Agents; Aspergillus; Bacillus subtilis; Mice; Microbial Sensitivity Tests; Molecular Structure; Nuclear Magnetic Resonance, Biomolecular; Sesquiterpenes; Staphylococcus aureus; Xanthones | 2016 |
Development of a Dual-Acting Antibacterial Agent (TNP-2092) for the Treatment of Persistent Bacterial Infections.
Topics: Anti-Bacterial Agents; Bacterial Infections; Dose-Response Relationship, Drug; Microbial Sensitivity Tests; Molecular Structure; Rifamycins; Staphylococcus aureus; Structure-Activity Relationship | 2016 |
Hybrid Antibiotic Overcomes Resistance in P. aeruginosa by Enhancing Outer Membrane Penetration and Reducing Efflux.
Topics: Anti-Bacterial Agents; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; Moxifloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2016 |
New 1,4-dihydro[1,8]naphthyridine derivatives as DNA gyrase inhibitors.
Topics: Anti-Bacterial Agents; Bacteria; DNA Gyrase; Enzyme Inhibitors; Microbial Sensitivity Tests; Naphthyridines | 2017 |
Amphiphilic Tobramycin-Lysine Conjugates Sensitize Multidrug Resistant Gram-Negative Bacteria to Rifampicin and Minocycline.
Topics: Anti-Bacterial Agents; Drug Resistance, Multiple, Bacterial; Gram-Negative Bacteria; Gram-Positive Bacteria; Hemolysis; Lysine; Microbial Sensitivity Tests; Minocycline; Models, Biological; Rifampin; Tobramycin | 2017 |
Design, synthesis and biological evaluation of novel aryldiketo acids with enhanced antibacterial activity against multidrug resistant bacterial strains.
Topics: Anti-Bacterial Agents; Bacteria; Catalytic Domain; Chemistry Techniques, Synthetic; Drug Design; Drug Resistance, Multiple; Humans; Hydrophobic and Hydrophilic Interactions; Keto Acids; Molecular Docking Simulation; Serum Albumin, Human; Structure-Activity Relationship | 2018 |
Discovery and Optimization of Indolyl-Containing 4-Hydroxy-2-Pyridone Type II DNA Topoisomerase Inhibitors Active against Multidrug Resistant Gram-negative Bacteria.
Topics: Animals; Anti-Bacterial Agents; DNA Topoisomerases, Type II; Drug Discovery; Drug Resistance, Multiple, Bacterial; Female; Gram-Negative Bacteria; Mice; Microbial Sensitivity Tests; Models, Molecular; Molecular Structure; Protein Conformation; Pyridines; Sepsis; Structure-Activity Relationship; Topoisomerase II Inhibitors | 2018 |
Design, Synthesis, and Biological Evaluation of Novel 7-[(3 aS,7 aS)-3 a-Aminohexahydropyrano[3,4- c]pyrrol-2(3 H)-yl]-8-methoxyquinolines with Potent Antibacterial Activity against Respiratory Pathogens.
Topics: Animals; Anti-Bacterial Agents; Drug Design; Drug Evaluation, Preclinical; Drug Resistance, Bacterial; ERG1 Potassium Channel; Escherichia coli; Female; Humans; Macaca fascicularis; Male; Methicillin-Resistant Staphylococcus aureus; Mice, Inbred CBA; Microbial Sensitivity Tests; Pneumococcal Infections; Quinolines; Respiratory Tract Infections; Streptococcus pneumoniae | 2018 |
Synthesis, antituberculosis studies and biological evaluation of new quinoline derivatives carrying 1,2,4-oxadiazole moiety.
Topics: Antitubercular Agents; Dose-Response Relationship, Drug; Humans; Microbial Sensitivity Tests; Microsomes, Liver; Molecular Structure; Mycobacterium tuberculosis; Oxadiazoles; Quinolines; Structure-Activity Relationship | 2019 |
Polybasic peptide-levofloxacin conjugates potentiate fluoroquinolones and other classes of antibiotics against multidrug-resistant Gram-negative bacteria.
Topics: | 2019 |
Synthesis and biological evaluation of hybrid quinolone-based quaternary ammonium antibacterial agents.
Topics: Anti-Bacterial Agents; DNA Gyrase; DNA Topoisomerase IV; Dose-Response Relationship, Drug; Enzyme Inhibitors; Gram-Negative Bacteria; Gram-Positive Bacteria; HEK293 Cells; Humans; Microbial Sensitivity Tests; Molecular Structure; Quaternary Ammonium Compounds; Quinolones; Structure-Activity Relationship | 2019 |
The synthesis and in vitro biological evaluation of novel fluorinated tetrahydrobenzo[j]phenanthridine-7,12-diones against Mycobacterium tuberculosis.
Topics: Animals; Antitubercular Agents; Benzophenanthridines; Cell Line; Dose-Response Relationship, Drug; Humans; Hydrocarbons, Fluorinated; Macrophages; Mice; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Structure-Activity Relationship | 2019 |
Usnic Acid Enaminone-Coupled 1,2,3-Triazoles as Antibacterial and Antitubercular Agents.
Topics: Anti-Bacterial Agents; Antitubercular Agents; Bacillus subtilis; Benzofurans; Lichens; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Triazoles | 2020 |
Novel benzimidazole-acrylonitrile hybrids and their derivatives: Design, synthesis and antimycobacterial activity.
Topics: Acrylonitrile; Anti-Bacterial Agents; Benzimidazoles; Dose-Response Relationship, Drug; Drug Design; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Structure-Activity Relationship | 2020 |
Synthesis of Novel Ciprofloxacin-Based Hybrid Molecules toward Potent Antimalarial Activity.
Topics: | 2020 |
Novel C-7 carbon substituted fourth generation fluoroquinolones targeting N. Gonorrhoeae infections.
Topics: Anti-Bacterial Agents; Bacterial Infections; Carbon; Dose-Response Relationship, Drug; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Molecular Structure; Neisseria gonorrhoeae; Structure-Activity Relationship | 2020 |
Lipophilic quinolone derivatives: Synthesis and in vitro antibacterial evaluation.
Topics: Anti-Bacterial Agents; Dose-Response Relationship, Drug; Hydrophobic and Hydrophilic Interactions; Microbial Sensitivity Tests; Molecular Structure; Neisseria gonorrhoeae; Quinolones; Structure-Activity Relationship | 2022 |
Synthesis and evaluation of dual-action kanglemycin-fluoroquinolone hybrid antibiotics.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Escherichia coli; Fluoroquinolones; HEK293 Cells; Humans; Microbial Sensitivity Tests; Rifamycins; Staphylococcus aureus | 2022 |
WCK 1152, WCK 1153: Discovery and structure activity relationship for the treatment of resistant pneumococcal and staphylococcal respiratory infections.
Topics: Anti-Bacterial Agents; DNA Gyrase; DNA Topoisomerase IV; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Piperidines; Respiratory Tract Infections; Staphylococcal Infections; Staphylococcus; Streptococcus pneumoniae; Structure-Activity Relationship | 2022 |
Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Ciprofloxacin; Enterobacteriaceae; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolines; Quinolones; Staphylococcus aureus | 1997 |
In vitro activities of six fluoroquinolones against Canadian isolates of vancomycin-sensitive and vancomycin-resistant Enterococcus species.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Canada; Ciprofloxacin; Drug Resistance, Microbial; Enterococcus; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Quinolones; Vancomycin | 1998 |
In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to BAY 12-8039, trovafloxacin, and ciprofloxacin.
Topics: Anti-Infective Agents; Aza Compounds; Bordetella; Bordetella pertussis; Ciprofloxacin; Fluoroquinolones; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Quinolines; Quinolones | 1998 |
Intracellular activity of ciprofloxacin and moxifloxacin, a new 8-methoxyquinolone, against methicillin-resistant Staphylococcus aureus.
Topics: Anti-Infective Agents; Aza Compounds; Cells, Cultured; Ciprofloxacin; Fluoroquinolones; Humans; Leukocytes, Mononuclear; Methicillin Resistance; Microbial Sensitivity Tests; Moxifloxacin; Phagocytosis; Quinolines; Quinolones; Staphylococcus aureus | 1998 |
Uptake and intracellular activity of moxifloxacin in human neutrophils and tissue-cultured epithelial cells.
Topics: Anti-Infective Agents; Aza Compounds; Cells, Cultured; Ciprofloxacin; Epithelial Cells; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Neutrophils; Ofloxacin; Quinolines; Staphylococcus aureus | 1999 |
Comparative activities of clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacin, and trovafloxacin and nonquinolones linozelid, quinupristin-dalfopristin, gentamicin, and vancomycin against clinical isolates of ciprofloxacin-re
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Gentamicins; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolines; Quinolones; Staphylococcus aureus; Vancomycin; Virginiamycin | 1999 |
The effect of reserpine, an inhibitor of multidrug efflux pumps, on the in-vitro activities of ciprofloxacin, sparfloxacin and moxifloxacin against clinical isolates of Staphylococcus aureus.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Genes, Bacterial; Humans; Methicillin Resistance; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Polymerase Chain Reaction; Quinolines; Reserpine; Staphylococcal Infections; Staphylococcus aureus | 1998 |
The in-vitro activity of moxifloxacin against Legionella species and the effects of medium on susceptibility test results.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Antibiotics, Antitubercular; Aza Compounds; Ciprofloxacin; Culture Media; Drug Resistance, Microbial; Erythromycin; Fluoroquinolones; Legionella; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Rifampin | 1999 |
Antimicrobial activity and accumulation of moxifloxacin in quinolone-susceptible bacteria.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Escherichia coli; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Haemophilus influenzae; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Pseudomonas aeruginosa; Quinolines; Staphylococcus aureus; Streptococcus pneumoniae | 1999 |
Antibacterial activity of moxifloxacin (Bay 12-8039) against aerobic clinical isolates, and provisional criteria for disk susceptibility tests.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria, Aerobic; Ciprofloxacin; Fluoroquinolones; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines | 1999 |
Comparative in-vitro activity of moxifloxacin, penicillin, ceftriaxone and ciprofloxacin against pneumococci isolated from meningitis.
Topics: Anti-Bacterial Agents; Aza Compounds; Ceftriaxone; Ciprofloxacin; Fluoroquinolones; Humans; Meningitis, Pneumococcal; Microbial Sensitivity Tests; Moxifloxacin; Penicillins; Pneumococcal Infections; Quinolines; Streptococcus pneumoniae | 1999 |
Comparative in vitro activities of ciprofloxacin, clinafloxacin, gatifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, and Enterobacter aerogenes clinical isolates with alterat
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; DNA Topoisomerases, Type II; Enterobacter cloacae; Fluoroquinolones; Gatifloxacin; Humans; Klebsiella pneumoniae; Levofloxacin; Microbial Sensitivity Tests; Molecular Sequence Data; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines | 1999 |
Activity of moxifloxacin against pathogens with decreased susceptibility to ciprofloxacin.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Microbial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Quinolines; Staphylococcus aureus; Streptococcus pneumoniae | 1999 |
Comparative in vitro activities of ciprofloxacin, gemifloxacin, grepafloxacin, moxifloxacin, ofloxacin, sparfloxacin, trovafloxacin, and other antimicrobial agents against bloodstream isolates of gram-positive cocci.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Bacteremia; Ciprofloxacin; Fluoroquinolones; Gemifloxacin; Gram-Positive Bacterial Infections; Gram-Positive Cocci; Humans; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolines | 2000 |
Comparative activities of ciprofloxacin, clinafloxacin, gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against epidemiologically defined Acinetobacter baumannii strains.
Topics: Acinetobacter; Acinetobacter Infections; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Disease Outbreaks; Drug Resistance, Microbial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Germany; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines | 2000 |
In vitro activity of new generation fluoroquinolones against genotypically distinct and indistinguishable Clostridium difficile isolates.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Clostridioides difficile; Fluoroquinolones; Genotype; Humans; Microbial Sensitivity Tests; Moxifloxacin; Quinolines | 2000 |
Effects of sparfloxacin, grepafloxacin, moxifloxacin, and ciprofloxacin on cardiac action potential duration.
Topics: Action Potentials; Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Dogs; Female; Fluoroquinolones; Heart; Male; Moxifloxacin; Piperazines; Quinolines; Time Factors | 2000 |
In vitro activity of gatifloxacin compared with gemifloxacin, moxifloxacin, trovafloxacin, ciprofloxacin and ofloxacin against uropathogens cultured from patients with complicated urinary tract infections.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Escherichia coli; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Klebsiella; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Urinary Tract Infections | 2000 |
Capillary electrophoresis with laser-induced fluorescence in clinical drug development routine application and future aspects.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Drug Design; Electrophoresis, Capillary; Fluoroquinolones; Lasers; Moxifloxacin; Quinolines; Sensitivity and Specificity; Spectrometry, Fluorescence | 2000 |
Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Colony Count, Microbial; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Models, Biological; Moxifloxacin; Naphthyridines; Ofloxacin; Piperazines; Quinolines; Streptococcus pneumoniae; Time Factors | 2001 |
Antimicrobial activity of fluoroquinolone photodegradation products determined by parallel-line bioassay and high performance liquid chromatography.
Topics: Anti-Infective Agents; Aza Compounds; Biological Assay; Chromatography, High Pressure Liquid; Ciprofloxacin; Dose-Response Relationship, Drug; Enterobacter cloacae; Escherichia coli; Fluoroquinolones; Klebsiella; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Photochemistry; Quinolines | 2001 |
Activity of moxifloxacin against clinical isolates of Streptococcus pneumoniae from England and Wales.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Microbial; England; Fluoroquinolones; Hospitals; Humans; Microbial Sensitivity Tests; Moxifloxacin; Pneumococcal Infections; Quinolines; Streptococcus pneumoniae; Wales | 2001 |
In vitro activity of four fluoroquinolones against Mycobacterium tuberculosis.
Topics: Anti-Infective Agents; Antitubercular Agents; Aza Compounds; Ciprofloxacin; Dose-Response Relationship, Drug; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Quinolines; Spain | 2001 |
The effect of albumin, globulin, pus and dead bacteria in aerobic and anaerobic conditions on the antibacterial activity of moxifloxacin, trovafloxacin and ciprofloxacin against Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli.
Topics: Albumins; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Escherichia coli; Escherichia coli Infections; Fluoroquinolones; Globulins; Gram-Positive Bacterial Infections; Humans; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Pneumococcal Infections; Quinolines; Staphylococcal Infections; Staphylococcus aureus; Streptococcus pneumoniae; Suppuration | 2000 |
Bactericidal activity of moxifloxacin against Staphylococcus aureus.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Endocarditis, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Staphylococcal Infections; Staphylococcus aureus | 2001 |
Activity of moxifloxacin and other quinolones against pneumococci resistant to first-line agents, or with high-level ciprofloxacin resistance.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Microbial; Drug Resistance, Multiple; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Piperazines; Quinolines; Streptococcus pneumoniae | 2001 |
A comparison of the bactericidal activity of quinolone antibiotics in a Mycobacterium fortuitum model.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Drug Resistance, Multiple; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Models, Biological; Moxifloxacin; Mycobacterium fortuitum; Mycobacterium Infections, Nontuberculous; Ofloxacin; Quinolines | 2001 |
Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: Report from The SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States.
Topics: Anti-Infective Agents; Aza Compounds; Canada; Ciprofloxacin; Europe; Fluoroquinolones; Gatifloxacin; Haemophilus influenzae; Humans; Indoles; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Ofloxacin; Quinolines; Quinolones; United States | 2001 |
gyrA mutations associated with quinolone resistance in Bacteroides fragilis group strains.
Topics: Amino Acid Substitution; Anti-Infective Agents; Aza Compounds; Bacteroides fragilis; Ciprofloxacin; DNA Gyrase; DNA Topoisomerases, Type II; Drug Resistance, Microbial; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Ofloxacin; Quinolines | 2001 |
Immunomodulatory effects of moxifloxacin in comparison to ciprofloxacin and G-CSF in a murine model of cyclophosphamide-induced leukopenia.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Bone and Bones; Bone Marrow Cells; Cell Count; Ciprofloxacin; Culture Media, Conditioned; Culture Techniques; Cyclophosphamide; Cytokines; Disease Models, Animal; Fluoroquinolones; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Granulocytes; Hematopoiesis; Hematopoietic Stem Cells; Humans; Immunity; Interleukin-6; Leukocyte Count; Leukopenia; Lung; Male; Mice; Mice, Inbred BALB C; Moxifloxacin; Quinolines; Quinolones; Spleen; Urinary Bladder | 2001 |
Single- and multi-step resistance selection study of gemifloxacin compared with trovafloxacin, ciprofloxacin, gatifloxacin and moxifloxacin in Streptococcus pneumoniae.
Topics: Anti-Infective Agents; Aza Compounds; Biological Transport; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Microbial; Drug Resistance, Multiple; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Naphthyridines; Quinolines; Selection, Genetic; Serotyping; Streptococcus pneumoniae | 2001 |
Comparison of the in vitro activities of BMS-284756 and four fluoroquinolones against Streptococcus pneumoniae.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Fluoroquinolones; Humans; Indoles; Microbial Sensitivity Tests; Moxifloxacin; Norfloxacin; Quinolines; Quinolones; Streptococcus pneumoniae | 2001 |
Ciprofloxacin- and methicillin-resistant staphylococcus aureus susceptible to moxifloxacin, levofloxacin, teicoplanin, vancomycin and linezolid.
Topics: Acetamides; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Base Sequence; Ciprofloxacin; Drug Resistance, Multiple; Fluoroquinolones; Humans; Levofloxacin; Linezolid; Methicillin Resistance; Microbial Sensitivity Tests; Molecular Sequence Data; Moxifloxacin; Ofloxacin; Oxazolidinones; Polymerase Chain Reaction; Quinolines; Sensitivity and Specificity; Staphylococcus aureus; Teicoplanin; Vancomycin | 2001 |
Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; DNA Gyrase; Drug Resistance, Microbial; Endocarditis, Bacterial; Fluoroquinolones; Methicillin Resistance; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Rats; Spleen; Staphylococcal Infections; Staphylococcus aureus; Vancomycin | 2001 |
Multicentre study of the in vitro evaluation of moxifloxacin and other quinolones against community acquired respiratory pathogens.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Ciprofloxacin; Community-Acquired Infections; Fluoroquinolones; Haemophilus influenzae; Humans; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Respiratory Tract Infections; Streptococcus pneumoniae; Streptococcus pyogenes | 2001 |
Accumulation of five fluoroquinolones by Mycobacterium tuberculosis H37Rv.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Norfloxacin; Ofloxacin; Quinolines | 2001 |
Single or double mutational alterations of gyrA associated with fluoroquinolone resistance in Campylobacter jejuni and Campylobacter coli.
Topics: Anti-Infective Agents; Aza Compounds; Campylobacter coli; Campylobacter jejuni; Ciprofloxacin; DNA Gyrase; DNA, Bacterial; Drug Resistance, Microbial; Fluoroquinolones; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Nalidixic Acid; Quinolines; Reverse Transcriptase Polymerase Chain Reaction | 2001 |
Rates of torsades de pointes associated with ciprofloxacin, ofloxacin, levofloxacin, gatifloxacin, and moxifloxacin.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Electrocardiography; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Moxifloxacin; Ofloxacin; Quinolines; Retrospective Studies; Torsades de Pointes | 2001 |
Minimal inhibitory concentrations and time-kill determination of moxifloxacin against aerobic and anaerobic isolates.
Topics: Aerobiosis; Anaerobiosis; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Bacteria; Ceftriaxone; Cephalosporins; Ciprofloxacin; Clindamycin; Clostridium; Drug Resistance, Multiple, Bacterial; Erythromycin; Fluoroquinolones; Imipenem; Microbial Sensitivity Tests; Moxifloxacin; Mycoplasma; Quinolines; Streptococcus; Teicoplanin; Thienamycins; Vancomycin | 2002 |
Evidence of active efflux in resistance to ciprofloxacin and to ethidium bromide by Mycoplasma hominis.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Microbial; Enzyme Inhibitors; Ethidium; Fluoroquinolones; Genes, MDR; Microbial Sensitivity Tests; Moxifloxacin; Mycoplasma hominis; Pefloxacin; Phenotype; Quinolines; Reverse Transcriptase Polymerase Chain Reaction | 2002 |
[Activity of new fluoroquinolones against clinical isolates of Acinetobacter baumannii].
Topics: Acinetobacter; Acinetobacter Infections; Ampicillin; Anti-Infective Agents; Aza Compounds; Cefepime; Cephalosporins; Ciprofloxacin; Colistin; Fluoroquinolones; Gatifloxacin; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Moxifloxacin; Nalidixic Acid; Naphthyridines; Norfloxacin; Ofloxacin; Opportunistic Infections; Quinolines; Sulbactam; Thienamycins | 2001 |
[In vitro activity of six fluoroquinolones and penicillin against 101 viridans group streptococci characterized by their susceptibility to erythromycin].
Topics: Anti-Infective Agents; Aza Compounds; Bacteremia; Ciprofloxacin; Drug Resistance; Drug Resistance, Multiple, Bacterial; Erythromycin; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Norfloxacin; Ofloxacin; Penicillins; Quinolines; Streptococcal Infections; Streptococcus | 2001 |
Fourth generation fluoroquinolones: new weapons in the arsenal of ophthalmic antibiotics.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Ciprofloxacin; Drug Resistance, Microbial; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Retrospective Studies | 2002 |
Lack of interaction of fluoroquinolones with lipopolysaccharides.
Topics: Anti-Infective Agents; Aza Compounds; Cations, Divalent; Cell Membrane; Ciprofloxacin; Fluoroquinolones; Lipopolysaccharides; Magnesium Chloride; Moxifloxacin; Quinolines; Salmonella enterica | 2002 |
Comparative intracellular (THP-1 macrophage) and extracellular activities of beta-lactams, azithromycin, gentamicin, and fluoroquinolones against Listeria monocytogenes at clinically relevant concentrations.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Azithromycin; beta-Lactams; Ciprofloxacin; Fluoroquinolones; Gentamicins; Humans; Listeria monocytogenes; Macrophages; Microbial Sensitivity Tests; Moxifloxacin; Quinolines | 2002 |
Single- and multistep selection study of the antipneumococcal activity of BMS-284756 compared to ciprofloxacin, levofloxacin, trovafloxacin and moxifloxacin.
Topics: Anti-Infective Agents; Aza Compounds; Biological Transport; Ciprofloxacin; Drug Resistance, Microbial; Drug Resistance, Multiple; Fluoroquinolones; Humans; Indoles; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Quinolones; Streptococcus pneumoniae | 2002 |
gyrA and gyrB mutations are implicated in cross-resistance to Ciprofloxacin and moxifloxacin in Clostridium difficile.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Clostridioides difficile; DNA Gyrase; DNA, Fungal; Drug Resistance, Bacterial; Enterocolitis, Pseudomembranous; Fluoroquinolones; Genotype; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Quinolines; Reverse Transcriptase Polymerase Chain Reaction | 2002 |
Moxifloxacin activity against clinical isolates compared with the activity of ciprofloxacin.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Microbial Sensitivity Tests; Moxifloxacin; Quinolines | 2002 |
Antianaerobic activity of moxifloxacin compared with that of ofloxacin, ciprofloxacin, clindamycin, metronidazole and beta-lactams.
Topics: Anaerobiosis; Anti-Bacterial Agents; Aza Compounds; Bacterial Infections; beta-Lactams; Ciprofloxacin; Clindamycin; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Metronidazole; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines | 2002 |
In vitro activity of gemifloxacin against recent clinical isolates of bacteria in Korea.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Haemophilus influenzae; Korea; Levofloxacin; Microbial Sensitivity Tests; Moraxella; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2002 |
[Pneumococcus and quinolone resistance].
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Child, Preschool; Ciprofloxacin; DNA, Bacterial; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Genes, Bacterial; Humans; Male; Microbial Sensitivity Tests; Moxifloxacin; Multivariate Analysis; Mutation; Ofloxacin; Penicillin Resistance; Penicillins; Pneumococcal Infections; Pneumonia, Pneumococcal; Quinolines; Recurrence; Risk Factors; Streptococcus pneumoniae | 2003 |
Activity of and resistance to moxifloxacin in Staphylococcus aureus.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Moxifloxacin; Mutation; Quinolines; Staphylococcus aureus; Topoisomerase II Inhibitors | 2003 |
Simulated in vitro quinolone pharmacodynamics at clinically achievable AUC/MIC ratios: advantage of I E over other integral parameters.
Topics: Anti-Bacterial Agents; Area Under Curve; Aza Compounds; Ciprofloxacin; Fluoroquinolones; Gemifloxacin; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Quinolones; Time Factors | 2002 |
In vitro and in vivo activities of fluoroquinolones against Aeromonas hydrophila.
Topics: Aeromonas hydrophila; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Cefotaxime; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacterial Infections; Humans; In Vitro Techniques; Levofloxacin; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Minocycline; Moxifloxacin; Ofloxacin; Quinolines; Quinolones | 2003 |
Quantitative analysis of gentamicin, azithromycin, telithromycin, ciprofloxacin, moxifloxacin, and oritavancin (LY333328) activities against intracellular Staphylococcus aureus in mouse J774 macrophages.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Azithromycin; Ciprofloxacin; Fluoroquinolones; Gentamicins; Glycopeptides; Lipoglycopeptides; Lymphoma, Large B-Cell, Diffuse; Macrophages; Mice; Microbial Sensitivity Tests; Microscopy, Electron; Moxifloxacin; Quinolines; Staphylococcal Infections; Staphylococcus aureus; Tumor Cells, Cultured | 2003 |
Susceptibilities of Campylobacter jejuni isolates from Germany to ciprofloxacin, moxifloxacin, erythromycin, clindamycin, and tetracycline.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Campylobacter jejuni; Ciprofloxacin; Clindamycin; Drug Resistance, Bacterial; Erythromycin; Fluoroquinolones; Germany; Humans; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Tetracycline | 2003 |
In vitro activity of gemifloxacin against clinical isolates of Neisseria gonorrhoeae with and without mutations in the gyrA gene.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Gemifloxacin; Genes, Bacterial; Gonorrhea; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Nalidixic Acid; Naphthyridines; Neisseria gonorrhoeae; Ofloxacin; Quinolines | 2003 |
Comparative in vitro activity of three fluoroquinolones against clinical isolates by E test.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Fluoroquinolones; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines | 2003 |
Accumulation of garenoxacin by Bacteroides fragilis compared with that of five fluoroquinolones.
Topics: Aza Compounds; Bacteroides fragilis; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Levofloxacin; Membrane Transport Modulators; Membrane Transport Proteins; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines | 2003 |
Gatifloxacin and moxifloxacin: an in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Ciprofloxacin; Corneal Ulcer; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines | 2003 |
Prulifloxacin: in vitro (HERG current) and in vivo (conscious dog) assessment of cardiac risk.
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Aza Compounds; Cell Line; Ciprofloxacin; Dioxolanes; DNA-Binding Proteins; Dogs; Fluoroquinolones; In Vitro Techniques; Moxifloxacin; Patch-Clamp Techniques; Piperazines; Potassium Channel Blockers; Quinolines; Quinolones; Telemetry; Trans-Activators; Transcriptional Regulator ERG | 2003 |
Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolones.
Topics: Aza Compounds; Bacteroides fragilis; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2003 |
Activities of ciprofloxacin and moxifloxacin against Stenotrophomonas maltophilia and emergence of resistant mutants in an in vitro pharmacokinetic-pharmacodynamic model.
Topics: Anti-Infective Agents; Area Under Curve; Aza Compounds; Ciprofloxacin; Colony-Forming Units Assay; Drug Resistance, Bacterial; Fluoroquinolones; Half-Life; Microbial Sensitivity Tests; Models, Biological; Moxifloxacin; Mutation; Quinolines; Stenotrophomonas maltophilia | 2004 |
Laboratory detection of Haemophilus influenzae with decreased susceptibility to nalidixic acid, ciprofloxacin, levofloxacin, and moxifloxacin due to GyrA and ParC mutations.
Topics: Aza Compounds; Base Sequence; Ciprofloxacin; DNA Gyrase; DNA Primers; DNA Topoisomerase IV; Fluoroquinolones; Haemophilus Infections; Haemophilus influenzae; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Nalidixic Acid; Ofloxacin; Polymerase Chain Reaction; Quinolines | 2004 |
Susceptibility testing of Singapore strains of Mycoplasma hominis to tetracycline, gatifloxacin, moxifloxacin, ciprofloxacin, clindamycin, and azithromycin by the Etest method.
Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Ciprofloxacin; Clindamycin; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mycoplasma hominis; Quinolines; Sampling Studies; Sensitivity and Specificity; Singapore; Tetracycline | 2004 |
Apparent failure of moxifloxacin to prevent ciprofloxacin- and levofloxacin-susceptible Pseudomonas aeruginosa bacteremia in neutropenic patients undergoing peripheral blood stem cell transplantation.
Topics: Anti-Infective Agents; Aza Compounds; Bacteremia; Ciprofloxacin; Female; Fluoroquinolones; Hematopoietic Stem Cell Transplantation; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Neutropenia; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines; Treatment Failure | 2004 |
Effectiveness of ciprofloxacin, levofloxacin, or moxifloxacin for treatment of experimental Staphylococcus aureus keratitis.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Cornea; Drug Resistance, Bacterial; Fluoroquinolones; Keratitis; Levofloxacin; Moxifloxacin; Ofloxacin; Quinolines; Rabbits; Staphylococcal Infections | 2004 |
Post-exposure prophylaxis of systemic anthrax in mice and treatment with fluoroquinolones.
Topics: Animals; Anthrax; Anti-Infective Agents; Aza Compounds; Bacillus anthracis; Ciprofloxacin; Female; Fluoroquinolones; Gatifloxacin; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Survival Analysis | 2004 |
Activities of different fluoroquinolones against Bacillus anthracis mutants selected in vitro and harboring topoisomerase mutations.
Topics: Anti-Infective Agents; Aza Compounds; Bacillus anthracis; Ciprofloxacin; DNA Gyrase; DNA Primers; DNA Topoisomerase IV; DNA Topoisomerases, Type I; DNA, Bacterial; Drug Resistance, Bacterial; Fluoroquinolones; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Quinolines; Reverse Transcriptase Polymerase Chain Reaction | 2004 |
Quantitative comparison of fluoroquinolone therapies of experimental gram-negative bacterial keratitis.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Colony Count, Microbial; Cornea; Eye Infections, Bacterial; Fluoroquinolones; Keratitis; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines; Rabbits; Serratia Infections; Serratia marcescens | 2004 |
Susceptibility of Mexican brucella isolates to moxifloxacin, ciprofloxacin and other antimicrobials used in the treatment of human brucellosis.
Topics: Anti-Bacterial Agents; Aza Compounds; Brucella; Brucellosis; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; Mexico; Microbial Sensitivity Tests; Moxifloxacin; Quinolines; Sensitivity and Specificity | 2004 |
Effect of low-level resistance on subsequent enrichment of fluoroquinolone-resistant Streptococcus pneumoniae in rabbits.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Lung; Moxifloxacin; Mutation; Pneumococcal Infections; Quinolines; Rabbits; Streptococcus pneumoniae | 2004 |
Quinolone-resistant Haemophilus influenzae: determination of mutant selection window for ciprofloxacin, garenoxacin, levofloxacin, and moxifloxacin.
Topics: Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Haemophilus influenzae; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Ofloxacin; Quinolines; Reverse Transcriptase Polymerase Chain Reaction | 2004 |
In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Disease Models, Animal; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Female; Fluoroquinolones; Gemifloxacin; Levofloxacin; Mice; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Ofloxacin; Pneumococcal Infections; Point Mutation; Quinolines; Sepsis; Streptococcus pneumoniae; Treatment Outcome | 2005 |
Comparative efficacy of topical moxifloxacin versus ciprofloxacin and vancomycin in the treatment of P. aeruginosa and ciprofloxacin-resistant MRSA keratitis in rabbits.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Colony Count, Microbial; Corneal Stroma; Drug Resistance, Multiple, Bacterial; Eye Infections, Bacterial; Fluoroquinolones; Keratitis; Methicillin Resistance; Moxifloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines; Rabbits; Staphylococcal Infections; Staphylococcus aureus; Vancomycin | 2005 |
Comparative activity of quinolones (ciprofloxacin, levofloxacin, moxifloxacin and garenoxacin) against extracellular and intracellular infection by Listeria monocytogenes and Staphylococcus aureus in J774 macrophages.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Cell Line, Tumor; Ciprofloxacin; Fluoroquinolones; Levofloxacin; Listeria monocytogenes; Macrophages; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Staphylococcus aureus; Time Factors | 2005 |
Comparison of gatifloxacin, moxifloxacin and ciprofloxacin for treatment of experimental Burkholderia pseudomallei infection.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Dexamethasone; Drug Administration Schedule; Female; Fluoroquinolones; Gatifloxacin; Glucocorticoids; Melioidosis; Mice; Mice, Inbred BALB C; Moxifloxacin; Quinolines | 2005 |
Vibrational spectroscopic characterization of fluoroquinolones.
Topics: Aza Compounds; Cinoxacin; Ciprofloxacin; DNA Gyrase; DNA, Bacterial; Enoxacin; Enzyme Inhibitors; Fluoroquinolones; Hydrogen Bonding; Hydrogen-Ion Concentration; Models, Chemical; Models, Molecular; Models, Theoretical; Moxifloxacin; Nalidixic Acid; Norfloxacin; Ofloxacin; Oxolinic Acid; Quinolines; Quinolones; Spectrophotometry, Infrared; Spectrum Analysis, Raman; Temperature; Ultraviolet Rays; Vibration; Water | 2005 |
Infected cat-bite wound treated successfully with moxifloxacin after failure of parenteral cefuroxime and ciprofloxacin.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Bites and Stings; Cats; Cefuroxime; Ciprofloxacin; Female; Fluoroquinolones; Humans; Middle Aged; Moxifloxacin; Pasteurella Infections; Quinolines; Streptococcal Infections; Treatment Failure; Wound Infection | 2005 |
Prophylactic use of moxifloxacin in patients receiving bone marrow transplants was not associated with increased ciprofloxacin resistance in Escherichia coli and enterococci.
Topics: Anti-Bacterial Agents; Aza Compounds; Bone Marrow Transplantation; Ciprofloxacin; Drug Resistance, Bacterial; Escherichia coli; Fluoroquinolones; Humans; Moxifloxacin; Quinolines; Streptococcaceae | 2005 |
Influence of efflux transporters on the accumulation and efflux of four quinolones (ciprofloxacin, levofloxacin, garenoxacin, and moxifloxacin) in J774 macrophages.
Topics: Anti-Infective Agents; Aza Compounds; Cell Line; Ciprofloxacin; Fluoroquinolones; Heat-Shock Response; Humans; Kinetics; Levofloxacin; Macrophages; Moxifloxacin; Ofloxacin; Quinolines; Quinolones | 2005 |
In vitro activity of fluoroquinolones against Mycobacterium tuberculosis.
Topics: Aza Compounds; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Quinolines; Quinolones; Sampling Studies; Sensitivity and Specificity | 2005 |
Differential effects of three antibiotics on T helper cell cytokine expression.
Topics: Adult; Anti-Bacterial Agents; Aza Compounds; Cells, Cultured; Ciprofloxacin; Clarithromycin; Cytokines; Dose-Response Relationship, Drug; Female; Fluoroquinolones; Humans; Interferon-gamma; Interleukin-4; Ionomycin; Lymphocyte Activation; Male; Middle Aged; Moxifloxacin; Quinolines; T-Lymphocytes, Helper-Inducer; Tetradecanoylphorbol Acetate; Th1 Cells; Th2 Cells | 2005 |
The selection of resistance to and the mutagenicity of different fluoroquinolones in Staphylococcus aureus and Streptococcus pneumoniae.
Topics: Aza Compounds; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fluoroquinolones; Gemifloxacin; Levofloxacin; Moxifloxacin; Mutagenicity Tests; Naphthyridines; Ofloxacin; Quinolines; Selection, Genetic; Staphylococcus aureus; Streptococcus pneumoniae | 2005 |
Evaluation of moxifloxacin, ciprofloxacin, gatifloxacin, ofloxacin, and levofloxacin concentrations in human conjunctival tissue.
Topics: Anti-Bacterial Agents; Aza Compounds; Biopsy; Ciprofloxacin; Conjunctiva; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Moxifloxacin; Ofloxacin; Ophthalmic Solutions; Quinolines; Tissue Distribution | 2005 |
Distribution of fluoroquinolone MICs in Helicobacter pylori strains from Korean patients.
Topics: Amino Acid Substitution; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; DNA Gyrase; DNA, Bacterial; Drug Resistance, Bacterial; Fluoroquinolones; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Korea; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Point Mutation; Quinolines; Sequence Analysis, DNA | 2005 |
Glucose homeostasis abnormalities associated with use of gatifloxacin.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Child; Ciprofloxacin; Female; Fluoroquinolones; Gatifloxacin; Glucose; Homeostasis; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines | 2005 |
Microbiological rationale for the utilisation of prulifloxacin, a new fluoroquinolone, in the eradication of serious infections caused by Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Cystic Fibrosis; Dioxolanes; Drug Resistance, Bacterial; Fluoroquinolones; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Opportunistic Infections; Piperazines; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines; Quinolones | 2005 |
In vivo efficacy of fluoroquinolones against systemic tularaemia infection in mice.
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Colony Count, Microbial; Dexamethasone; Disease Models, Animal; Female; Fluoroquinolones; Francisella tularensis; Gatifloxacin; Mice; Mice, Inbred BALB C; Moxifloxacin; Quinolines; Survival Analysis; Tularemia | 2005 |
Clindamycin and quinolone therapy for Bacillus anthracis Sterne infection in 60Co-gamma-photon-irradiated and sham-irradiated mice.
Topics: Administration, Oral; Animals; Anthrax; Anti-Bacterial Agents; Aza Compounds; Bacillus anthracis; Blood; Ciprofloxacin; Clindamycin; Disease Models, Animal; Drug Therapy, Combination; Female; Fluoroquinolones; Gamma Rays; Injections, Subcutaneous; Liver; Lung; Mice; Moxifloxacin; Quinolines; Radiation Injuries, Experimental; Survival Analysis | 2005 |
T cell-mediated hypersensitivity to quinolones: mechanisms and cross-reactivity.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antigen-Presenting Cells; Aza Compounds; Cell Proliferation; Cells, Cultured; Ciprofloxacin; Clone Cells; Cross Reactions; Drug Hypersensitivity; Enoxacin; Female; Fluoroquinolones; Humans; Hypersensitivity, Delayed; Middle Aged; Moxifloxacin; Nalidixic Acid; Norfloxacin; Ofloxacin; Patch Tests; Pipemidic Acid; Quinolines; Quinolones; T-Lymphocytes | 2006 |
Effectiveness of fluoroquinolones against Mycobacterium abscessus in vivo.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Colony Count, Microbial; Corneal Stroma; Corneal Ulcer; Disease Models, Animal; Eye Infections, Bacterial; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium chelonae; Mycobacterium Infections, Nontuberculous; Ofloxacin; Ophthalmic Solutions; Quinolines; Rabbits | 2006 |
Evaluation of MGIT 960-based antimicrobial testing and determination of critical concentrations of first- and second-line antimicrobial drugs with drug-resistant clinical strains of Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; In Vitro Techniques; Isoniazid; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Quinolines; Rifampin; Tuberculosis, Pulmonary | 2006 |
Contribution of immunocompetence to the antibacterial activities of ciprofloxacin and moxifloxacin in an in vitro pharmacodynamic model.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Fluoroquinolones; Half-Life; Immunocompetence; Macrophages; Mice; Moxifloxacin; Pseudomonas aeruginosa; Quinolines; Rats; Staphylococcus aureus | 2005 |
Moxifloxacin and ciprofloxacin protect human respiratory epithelial cells against Streptococcus pneumoniae, Staphylococcus aureus, Pseudomonas aeruginosa, and Haemophilus influenzae in vitro.
Topics: Anti-Bacterial Agents; Aza Compounds; Cells, Cultured; Ciprofloxacin; Epithelial Cells; Fluoroquinolones; Haemophilus influenzae; Humans; Moxifloxacin; Pseudomonas aeruginosa; Quinolines; Respiratory System; Staphylococcus aureus; Streptococcus pneumoniae | 2005 |
Treatment of murine pneumonic Francisella tularensis infection with gatifloxacin, moxifloxacin or ciprofloxacin.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Female; Fluoroquinolones; Gatifloxacin; Mice; Mice, Inbred BALB C; Moxifloxacin; Pneumonia, Bacterial; Quinolines; Tularemia | 2006 |
Correlation of quinolone resistance levels and differences in basal and quinolone-induced expression from three qnrA-containing plasmids.
Topics: Anti-Infective Agents; Aza Compounds; Bacterial Proteins; Blotting, Northern; Blotting, Southern; Ciprofloxacin; Conjugation, Genetic; DNA, Bacterial; Drug Resistance, Bacterial; Escherichia coli; Fluoroquinolones; Gene Dosage; Gene Expression; Humans; Klebsiella Infections; Klebsiella pneumoniae; Moxifloxacin; Plasmids; Quinolines | 2006 |
Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Azithromycin; Cefuroxime; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Genes, Bacterial; Levofloxacin; Microbial Sensitivity Tests; Molecular Structure; Moxifloxacin; Naphthyridines; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2006 |
In vitro activities of DX-619 and comparison quinolones against gram-positive cocci.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Enterococcus; Fluoroquinolones; Gatifloxacin; Gram-Positive Cocci; In Vitro Techniques; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Pyrrolidines; Quinolines; Quinolones; Staphylococcus aureus; Streptococcus pneumoniae; Streptococcus pyogenes | 2006 |
Penetration of second-, third-, and fourth-generation topical fluoroquinolone into aqueous and vitreous humour in a rabbit endophthalmitis model.
Topics: Animals; Anti-Bacterial Agents; Aqueous Humor; Aza Compounds; Ciprofloxacin; Disease Models, Animal; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Levofloxacin; Moxifloxacin; Ofloxacin; Ophthalmic Solutions; Quinolines; Rabbits; Staphylococcal Infections; Vitreous Body | 2007 |
In vitro activity of fluoroquinolones against common respiratory pathogens.
Topics: Aza Compounds; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Haemophilus influenzae; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moraxella catarrhalis; Moxifloxacin; Ofloxacin; Quinolines; Streptococcus pneumoniae | 2006 |
Relation between induction of the mar operon and cyclohexane tolerance and reduction in fluoroquinolone susceptibility in Salmonella spp.
Topics: Anti-Bacterial Agents; Aspirin; Aza Compounds; Ciprofloxacin; Cyclohexanes; DNA Gyrase; Drug Resistance, Bacterial; Fluoroquinolones; Gene Expression Regulation, Bacterial; Humans; Moxifloxacin; Mutation; Nalidixic Acid; Operon; Quinolines; Salmonella | 2006 |
Moxifloxacin but not ciprofloxacin or azithromycin selectively inhibits IL-8, IL-6, ERK1/2, JNK, and NF-kappaB activation in a cystic fibrosis epithelial cell line.
Topics: Anti-Infective Agents; Aza Compounds; Azithromycin; Bronchi; Cell Line; Ciprofloxacin; Cystic Fibrosis; Epithelial Cells; Extracellular Signal-Regulated MAP Kinases; Fluoroquinolones; Humans; Interleukin-1beta; Interleukin-6; Interleukin-8; JNK Mitogen-Activated Protein Kinases; Lipopolysaccharides; Moxifloxacin; NF-kappa B; Phosphorylation; Quinolines; Tumor Necrosis Factor-alpha | 2007 |
In vitro development of resistance to DX-619 and other quinolones in enterococci.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacterial Proteins; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; DNA, Bacterial; Drug Resistance, Bacterial; Enterococcus faecalis; Enterococcus faecium; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Ofloxacin; Polymerase Chain Reaction; Pyrrolidines; Quinolines; Quinolones; Sequence Analysis, DNA | 2006 |
Molecular characterization of increasing fluoroquinolone resistance in Streptococcus pneumoniae isolates in Canada, 1997 to 2005.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Aza Compounds; Bacterial Proteins; Canada; Child; Child, Preschool; Ciprofloxacin; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Genotype; Humans; Infant; Infant, Newborn; Levofloxacin; Middle Aged; Moxifloxacin; Naphthyridines; Ofloxacin; Pneumococcal Infections; Quinolines; Serotyping; Streptococcus pneumoniae | 2007 |
Evaluation of the penetration of fluoroquinolones in human conjunctival tissue.
Topics: Anti-Bacterial Agents; Aza Compounds; Biopsy; Ciprofloxacin; Conjunctiva; Fluoroquinolones; Gatifloxacin; Humans; Moxifloxacin; Ofloxacin; Ophthalmic Solutions; Quinolines; Tissue Distribution | 2006 |
[Study investigating the activity of several fluoroquinolones against Pseudomonas aeruginosa using the mutant prevention concentration].
Topics: Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Cross Infection; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Genes, Bacterial; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutagenicity Tests; Mutation; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines | 2006 |
In vitro activity of fluoroquinolones against ocular bacterial isolates in São Paulo, Brazil.
Topics: Anti-Infective Agents; Aza Compounds; Bacteria; Brazil; Ciprofloxacin; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; In Vitro Techniques; Incidence; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines | 2007 |
The first steps towards fluoroquinolone resistance in Hungarian pneumococci.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacterial Proteins; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Hungary; Microbial Sensitivity Tests; Moxifloxacin; Mutation, Missense; Ofloxacin; Pneumococcal Infections; Quinolines; Streptococcus pneumoniae | 2006 |
Proarrhythmia as a class effect of quinolones: increased dispersion of repolarization and triangulation of action potential predict torsades de pointes.
Topics: Action Potentials; Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Disease Models, Animal; Dose-Response Relationship, Drug; Electrocardiography; Electrophysiologic Techniques, Cardiac; Fluoroquinolones; Heart Conduction System; In Vitro Techniques; Levofloxacin; Male; Moxifloxacin; Ofloxacin; Quinolines; Quinolones; Rabbits; Torsades de Pointes | 2007 |
Antimicrobial efficacy of gatifloxacin and moxifloxacin with and without benzalkonium chloride compared with ciprofloxacin and levofloxacin against methicillin-resistant Staphylococcus aureus.
Topics: Anti-Infective Agents; Aza Compounds; Benzalkonium Compounds; Cells, Cultured; Ciprofloxacin; Drug Combinations; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Methicillin Resistance; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Preservatives, Pharmaceutical; Quinolines; Staphylococcus aureus | 2007 |
Comparative minimal inhibitory and mutant prevention drug concentrations of four fluoroquinolones against ocular isolates of Haemophilus influenzae.
Topics: Anti-Infective Agents; Antimutagenic Agents; Aza Compounds; Ciprofloxacin; Dose-Response Relationship, Drug; Eye; Fluoroquinolones; Gatifloxacin; Haemophilus influenzae; Humans; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Osmolar Concentration; Quinolines | 2007 |
Comparative activities of antibiotics against intracellular non-typeable Haemophilus influenzae.
Topics: Adolescent; Adult; Ampicillin; Anti-Bacterial Agents; Aza Compounds; Azithromycin; Bacterial Typing Techniques; Bronchi; Cells, Cultured; Ciprofloxacin; Epithelial Cells; Female; Fluoroquinolones; Haemophilus influenzae; Humans; Ketolides; Male; Moxifloxacin; Quinolines | 2007 |
Comparison of antibiotic effect and corneal epithelial toxicity of levofloxacin and moxifloxacin in vitro.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacteriological Techniques; Cell Count; Cell Survival; Cells, Cultured; Ciprofloxacin; Colony Count, Microbial; Drug Resistance, Bacterial; Epithelium, Corneal; Fluoroquinolones; Humans; Levofloxacin; Methicillin Resistance; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Pseudomonas aeruginosa; Quinolines; Serratia marcescens; Staphylococcus aureus | 2007 |
Allometric scaling of marbofloxacin, moxifloxacin, danofloxacin and difloxacin pharmacokinetics: a retrospective analysis.
Topics: Animals; Anti-Infective Agents; Area Under Curve; Aza Compounds; Ciprofloxacin; Fluoroquinolones; Humans; Moxifloxacin; Quinolines; Quinolones; Retrospective Studies; Species Specificity | 2007 |
Intrinsic cytotoxic effects of fluoroquinolones on human corneal keratocytes and endothelial cells.
Topics: Anti-Bacterial Agents; Aza Compounds; Biological Assay; Ciprofloxacin; Cornea; Corneal Stroma; Endothelial Cells; Endothelium, Corneal; Fluoroquinolones; Gatifloxacin; Humans; In Vitro Techniques; Levofloxacin; Moxifloxacin; Ofloxacin; Quinolines | 2008 |
Characterization of the interactions between fluoroquinolone antibiotics and lipids: a multitechnique approach.
Topics: Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Complex Mixtures; Fluoroquinolones; Membrane Lipids; Membrane Microdomains; Microscopy, Atomic Force; Molecular Conformation; Moxifloxacin; Phase Transition; Phospholipids; Quinolines; Spectroscopy, Fourier Transform Infrared; Surface Properties | 2008 |
Quinolones as enhancers of camptothecin-induced cytotoxic and anti-topoisomerase I effects.
Topics: Antineoplastic Agents; Apoptosis; Aza Compounds; Camptothecin; Cell Line, Tumor; Ciprofloxacin; DNA; Fluoroquinolones; Humans; Interleukin-8; Moxifloxacin; Quinolines; Topoisomerase I Inhibitors; Vascular Endothelial Growth Factor A | 2008 |
Comparing the protective effects of ciprofloxacin, moxifloxacin and levofloxacin in mice with lipopolysaccharide-induced acute lung injuries.
Topics: Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Cytokines; Disease Models, Animal; Fluoroquinolones; Levofloxacin; Lipopolysaccharides; Mice; Mice, Inbred BALB C; Moxifloxacin; Ofloxacin; Quinolines; Respiratory Distress Syndrome | 2008 |
[Genetical conditioning of fluoroquinolone resistance mechanisms of clinical enterococcus faecalis strains. II. The mutations present in the qrdrs of gyrA, gyrB, parC and parE genes].
Topics: Amino Acid Substitution; Aza Compounds; Bacterial Proteins; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; DNA, Bacterial; Drug Resistance, Bacterial; Enterococcus faecalis; Fluoroquinolones; Genes, Bacterial; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Polymerase Chain Reaction; Quinolines; Species Specificity | 2007 |
Fluoroquinolone resistance during 2000-2005: an observational study.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Community-Acquired Infections; Drug Resistance, Multiple, Bacterial; Drug Utilization; Enterobacter aerogenes; Fluoroquinolones; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Microbial Sensitivity Tests; Moxifloxacin; Pharmacy Service, Hospital; Pneumonia, Bacterial; Quinolines | 2008 |
In vitro synergism of beta-lactams with ciprofloxacin and moxifloxacin against genetically distinct multidrug-resistant isolates of Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Aza Compounds; beta-Lactams; Ciprofloxacin; DNA Fingerprinting; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Drug Synergism; Electrophoresis, Gel, Pulsed-Field; Fluoroquinolones; Microbial Viability; Moxifloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines; Time Factors | 2008 |
Cooperation between prokaryotic (Lde) and eukaryotic (MRP) efflux transporters in J774 macrophages infected with Listeria monocytogenes: studies with ciprofloxacin and moxifloxacin.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Cell Line; Ciprofloxacin; Drug Resistance; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Listeria monocytogenes; Macrophages; Membrane Transport Proteins; Mice; Microbial Sensitivity Tests; Moxifloxacin; Multidrug Resistance-Associated Proteins; Quinolines | 2008 |
Novel gyrase mutations and characterization of ciprofloxacin-resistant clinical strains of Enterococcus faecalis isolated in Poland.
Topics: Amino Acid Substitution; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; DNA, Bacterial; Drug Resistance, Bacterial; Enterococcus faecalis; Fluoroquinolones; Genes, Bacterial; Gram-Positive Bacterial Infections; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Poland; Polymerase Chain Reaction; Quinolines; Sequence Analysis, DNA | 2008 |
[Resistance profiles to fluoroquinolones in clinical isolates of Gram positive cocci].
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Colombia; Dose-Response Relationship, Drug; Drug Resistance, Multiple, Bacterial; Enterococcus; Fluoroquinolones; Gatifloxacin; Humans; Moxifloxacin; Quinolines; Staphylococcal Infections; Staphylococcus aureus; Streptococcus pneumoniae | 2008 |
Third- and fourth-generation fluoroquinolones: retrospective comparison of endophthalmitis after cataract surgery performed over 10 years.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Antibiotic Prophylaxis; Aza Compounds; Ciprofloxacin; Cross-Sectional Studies; Endophthalmitis; Eye Infections, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Humans; Male; Middle Aged; Moxifloxacin; Ofloxacin; Phacoemulsification; Postoperative Complications; Prevalence; Quinolines; Retrospective Studies | 2008 |
Evaluation of toxicity of commercial ophthalmic fluoroquinolone antibiotics as assessed on immortalized corneal and conjunctival epithelial cells.
Topics: Anti-Infective Agents; Aza Compounds; Cell Line; Cell Survival; Ciprofloxacin; Conjunctiva; Drug Evaluation, Preclinical; Epithelial Cells; Epithelium, Corneal; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Moxifloxacin; Ofloxacin; Ophthalmic Solutions; Quinolines; Tetrazolium Salts; Thiazoles | 2008 |
Biofilm formation is not necessary for development of quinolone-resistant "persister" cells in an attached Staphylococcus epidermidis population.
Topics: Anti-Infective Agents; Aza Compounds; Bacterial Adhesion; Biofilms; Ciprofloxacin; Colony Count, Microbial; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Naphthyridines; Prosthesis-Related Infections; Quinolines; Quinolones; Staphylococcal Infections; Staphylococcus epidermidis | 2008 |
Determination of the inhibitory potential of 6 fluoroquinolones on CYP1A2 and CYP2C9 in human liver microsomes.
Topics: Animals; Anti-Infective Agents; Aryl Hydrocarbon Hydroxylases; Aza Compounds; Ciprofloxacin; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP2C9; Fluoroquinolones; Gatifloxacin; Humans; Isoenzymes; Levofloxacin; Microsomes, Liver; Molecular Structure; Moxifloxacin; Ofloxacin; Quinolines; Reproducibility of Results | 2008 |
The resistance patterns of normal ocular bacterial flora to 4 fluoroquinolone antibiotics.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacteria; Bacteria, Aerobic; Ciprofloxacin; Conjunctiva; Eye; Fluoroquinolones; Gatifloxacin; Gram-Positive Bacteria; Humans; In Vitro Techniques; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines | 2009 |
Comparative pharmacodynamic interaction analysis between ciprofloxacin, moxifloxacin and levofloxacin and antifungal agents against Candida albicans and Aspergillus fumigatus.
Topics: Anti-Bacterial Agents; Antifungal Agents; Aspergillus fumigatus; Aza Compounds; Candida albicans; Ciprofloxacin; Drug Antagonism; Drug Synergism; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines | 2009 |
Fluoroquinolones and postoperative endophthalmitis.
Topics: Anti-Infective Agents; Antibiotic Prophylaxis; Aza Compounds; Ciprofloxacin; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Moxifloxacin; Ofloxacin; Phacoemulsification; Postoperative Complications; Prevalence; Quinolines | 2009 |
Fluoroquinolones and postoperative endophthalmitis.
Topics: Anti-Infective Agents; Antibiotic Prophylaxis; Aza Compounds; Ciprofloxacin; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Moxifloxacin; Ofloxacin; Phacoemulsification; Postoperative Complications; Prevalence; Quinolines | 2009 |
Comparison of in vitro susceptibilities of Gram-positive cocci isolated from ocular infections against the second and fourth generation quinolones at a tertiary eye care centre in South India.
Topics: Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Eye Infections, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Gram-Positive Bacterial Infections; Humans; India; Male; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Quinolones; Retrospective Studies; Staphylococcus; Streptococcus | 2010 |
The mitochondria targeted antioxidant MitoQ protects against fluoroquinolone-induced oxidative stress and mitochondrial membrane damage in human Achilles tendon cells.
Topics: Achilles Tendon; Anti-Infective Agents; Antioxidants; Aza Compounds; Cell Survival; Cells, Cultured; Ciprofloxacin; Fluoroquinolones; Humans; Intracellular Membranes; Membrane Potential, Mitochondrial; Mitochondria; Moxifloxacin; Organophosphorus Compounds; Oxidative Stress; Quinolines; Rupture; Tendinopathy; Ubiquinone | 2009 |
Fluoroquinolone-resistant Brucella melitensis mutants obtained in vitro.
Topics: Anti-Bacterial Agents; Aza Compounds; Brucella melitensis; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; DNA, Bacterial; Drug Resistance, Bacterial; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Norfloxacin; Ofloxacin; Quinolines; Sequence Analysis, DNA | 2009 |
Pharmacokinetics of fluoroquinolones in critical care patients: A bio-analytical HPLC method for the simultaneous quantification of ofloxacin, ciprofloxacin and moxifloxacin in human plasma.
Topics: Aza Compounds; Chromatography, High Pressure Liquid; Ciprofloxacin; Fluoroquinolones; Humans; Moxifloxacin; Ofloxacin; Quinolines | 2009 |
Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antigens, Bacterial; Aza Compounds; Bacterial Outer Membrane Proteins; Bacterial Typing Techniques; Belgium; Carrier Proteins; Child; Child, Preschool; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Electrophoresis, Gel, Pulsed-Field; Fluoroquinolones; Humans; Infant; Membrane Transport Proteins; Middle Aged; Moxifloxacin; Quinolines; Streptococcal Infections; Streptococcus pyogenes; Young Adult | 2009 |
Exploration of the African green monkey as a preclinical pharmacokinetic model: oral pharmacokinetic parameters and drug-drug interactions.
Topics: Animals; Aza Compounds; Chlorocebus aethiops; Chromatography, High Pressure Liquid; Ciprofloxacin; Drug Evaluation, Preclinical; Erythromycin; Fluoroquinolones; Lidocaine; Mass Spectrometry; Models, Animal; Moxifloxacin; Pharmacokinetics; Phenytoin; Prednisolone; Propranolol; Quinolines; Species Specificity | 2009 |
Influence of type and neutralisation capacity of antacids on dissolution rate of ciprofloxacin and moxifloxacin from tablets.
Topics: Antacids; Anti-Infective Agents; Aza Compounds; Chemistry, Pharmaceutical; Ciprofloxacin; Fluoroquinolones; Hydrogen-Ion Concentration; Moxifloxacin; Quinolines; Tablets | 2009 |
Evaluation of the mutant selection window for fluoroquinolones against Neisseria gonorrhoeae.
Topics: Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Neisseria gonorrhoeae; Ofloxacin; Quinolines; Selection, Genetic | 2009 |
Comparison of fluoroquinolones: cytotoxicity on human corneal epithelial cells.
Topics: Anti-Infective Agents; Aza Compounds; Cell Survival; Cells, Cultured; Ciprofloxacin; Electric Impedance; Epithelial Cells; Epithelium, Corneal; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Moxifloxacin; Norfloxacin; Ofloxacin; Ophthalmic Solutions; Preservatives, Pharmaceutical; Quinolines | 2010 |
Phenotypic changes in ciprofloxacin-resistant Staphylococcus aureus.
Topics: Antibiotics, Antineoplastic; Aza Compounds; Bacterial Proteins; Ciprofloxacin; DNA Mismatch Repair; Drug Resistance, Bacterial; Fluoroquinolones; Gene Expression; Gene Expression Regulation, Bacterial; Mitomycin; Moxifloxacin; Multidrug Resistance-Associated Proteins; Mutation; Oligonucleotide Array Sequence Analysis; Phenotype; Quinolines; SOS Response, Genetics; Staphylococcus aureus | 2009 |
Validation of a MLC method with fluorescence detection for the determination of quinolones in urine samples by direct injection.
Topics: Anti-Bacterial Agents; Aza Compounds; Calibration; Chromatography, High Pressure Liquid; Ciprofloxacin; Fluorescence; Fluoroquinolones; Humans; Levofloxacin; Moxifloxacin; Ofloxacin; Quinolines; Quinolones; Reproducibility of Results | 2009 |
Antimicrobial susceptibility of moxifloxacin against gram-negative enteric rods from colombian patients with chronic periodontitis.
Topics: Adult; Aged; Amoxicillin-Potassium Clavulanate Combination; Anti-Infective Agents; Aza Compounds; Chi-Square Distribution; Chronic Periodontitis; Ciprofloxacin; Colombia; Dental Plaque; Enterobacteriaceae; Female; Fluoroquinolones; Gram-Negative Facultatively Anaerobic Rods; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Pseudomonas; Quinolines; Statistics, Nonparametric | 2010 |
Synthesis and antitubercular evaluation of new fluoroquinolone derivatives coupled with carbohydrates.
Topics: Antitubercular Agents; Aza Compounds; Carbohydrates; Ciprofloxacin; Fluoroquinolones; Gatifloxacin; Magnetic Resonance Spectroscopy; Microbial Sensitivity Tests; Molecular Structure; Moxifloxacin; Mycobacterium tuberculosis; Quinolines | 2010 |
Comparison of fluoroquinolone kinetics of kill in susceptible and resistant gram-positive conjunctival pathogens.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacteriological Techniques; Ciprofloxacin; Conjunctivitis, Bacterial; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Humans; In Vitro Techniques; Moxifloxacin; Ofloxacin; Quinolines; Staphylococcus aureus; Streptococcus pneumoniae; Time Factors | 2010 |
Immediate hypersensitivity to moxifloxacin with tolerance to ciprofloxacin: report of three cases and review of the literature.
Topics: Adult; Anti-Bacterial Agents; Aza Compounds; Bronchiectasis; Ciprofloxacin; Drug Eruptions; Drug Hypersensitivity; Female; Fluoroquinolones; Humans; Hypersensitivity, Immediate; Male; Middle Aged; Moxifloxacin; Quinolines; Skin Tests; Urticaria | 2010 |
Aqueous humor and plasma concentrations of ciprofloxacin and moxifloxacin following topical ocular administration in ophthalmologically normal horses.
Topics: Administration, Oral; Administration, Topical; Animals; Anti-Infective Agents; Aqueous Humor; Aza Compounds; Ciprofloxacin; Female; Fluoroquinolones; Horses; Male; Moxifloxacin; Orchiectomy; Quinolines | 2010 |
[Prevalence of Clostridium difficile in the gastrointestinal tract of hospitalized children under two years of age].
Topics: Aza Compounds; Ciprofloxacin; Clindamycin; Clostridioides difficile; Drug Resistance, Multiple, Bacterial; Erythromycin; Feces; Female; Fluoroquinolones; Gastrointestinal Tract; Gatifloxacin; Genotype; Humans; Infant; Infant, Newborn; Male; Metronidazole; Moxifloxacin; Phenotype; Quinolines; Species Specificity; Vancomycin | 2010 |
Susceptibility of rapidly growing mycobacteria isolated from cats and dogs, to ciprofloxacin, enrofloxacin and moxifloxacin.
Topics: Animals; Anti-Bacterial Agents; Australia; Aza Compounds; Cats; Ciprofloxacin; Diarrhea; Dogs; Enrofloxacin; Female; Fluoroquinolones; Male; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium; Quinolines | 2011 |
In vitro activity of nemonoxacin, tigecycline, and other antimicrobial agents against Helicobacter pylori isolates in Taiwan, 1998-2007.
Topics: Amino Acid Substitution; Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Clarithromycin; DNA Gyrase; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gemifloxacin; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Metronidazole; Microbial Sensitivity Tests; Minocycline; Moxifloxacin; Mutation; Naphthyridines; Ofloxacin; Quinolines; Quinolones; Sequence Analysis, Protein; Taiwan; Tetracyclines; Tigecycline | 2010 |
Effects of photodynamic therapy on rapidly growing nontuberculous mycobacteria keratitis.
Topics: Amikacin; Animals; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Colony Count, Microbial; Corneal Ulcer; Drug Synergism; Eye Infections, Bacterial; Fluoroquinolones; Methylene Blue; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium fortuitum; Mycobacterium Infections, Nontuberculous; Photochemotherapy; Quinolines; Rabbits | 2011 |
Tear, cornea, and aqueous humor concentrations of ciprofloxacin and moxifloxacin after topical ocular application in ophthalmologically normal horses.
Topics: Administration, Topical; Animals; Anti-Bacterial Agents; Aqueous Humor; Aza Compounds; Ciprofloxacin; Cornea; Fluoroquinolones; Horse Diseases; Horses; Keratitis; Moxifloxacin; Quinolines; Tears | 2011 |
Topical fluoroquinolone use as a risk factor for in vitro fluoroquinolone resistance in ocular cultures.
Topics: Administration, Topical; Aged; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Disk Diffusion Antimicrobial Tests; Drug Resistance, Multiple, Bacterial; Eye Infections, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Humans; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Quinolines; Risk Factors; Staphylococcal Infections; Staphylococcus aureus | 2011 |
Susceptibility of hamsters to infection by historic and epidemic BI Clostridium difficile strains during daily administration of three fluoroquinolones.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Clostridioides difficile; Clostridium Infections; Cricetinae; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Male; Mesocricetus; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Prohibitins; Quinolines | 2011 |
[Regional difference of antibiotic resistance of helicobacter pylori strains in Korea].
Topics: Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Azithromycin; Ciprofloxacin; Clarithromycin; Drug Resistance, Bacterial; Female; Fluoroquinolones; Helicobacter Infections; Helicobacter pylori; Humans; Levofloxacin; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Ofloxacin; Quinolines; Republic of Korea; Tetracycline | 2011 |
JNJ-Q2, a new fluoroquinolone with potent in vitro activity against Staphylococcus aureus, including methicillin- and fluoroquinolone-resistant strains.
Topics: Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Levofloxacin; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Staphylococcus aureus | 2011 |
Comparison of the chromatographic behavior of levofloxacin, ciprofloxacin and moxifloxacin on various HPLC phases.
Topics: Anti-Bacterial Agents; Aza Compounds; Calixarenes; Chromatography, High Pressure Liquid; Ciprofloxacin; Fluoroquinolones; Hydrogen-Ion Concentration; Indicators and Reagents; Ions; Levofloxacin; Moxifloxacin; Ofloxacin; Quinolines; Reference Standards; Solutions | 2011 |
Susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada.
Topics: Anti-Bacterial Agents; Aza Compounds; Binding Sites; Canada; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Pneumococcal Infections; Quinolines; Streptococcus pneumoniae | 2011 |
Comparison of the bactericidal activity of various fluoroquinolones against Mycobacterium tuberculosis in an in vitro experimental model.
Topics: Antitubercular Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Isoniazid; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Quinolines; Spain; Tuberculosis | 2011 |
Cellular accumulation of fluoroquinolones is not predictive of their intracellular activity: studies with gemifloxacin, moxifloxacin and ciprofloxacin in a pharmacokinetic/pharmacodynamic model of uninfected and infected macrophages.
Topics: Animals; Anti-Bacterial Agents; Aza Compounds; Cell Line; Ciprofloxacin; Fluoroquinolones; Gemifloxacin; Humans; Listeria monocytogenes; Macrophages; Mice; Microbial Sensitivity Tests; Moxifloxacin; Naphthyridines; Quinolines; Staphylococcus aureus | 2011 |
Modulation of the expression of ABC transporters in murine (J774) macrophages exposed to large concentrations of the fluoroquinolone antibiotic moxifloxacin.
Topics: Animals; Anti-Infective Agents; ATP-Binding Cassette Transporters; Aza Compounds; Cell Line; Ciprofloxacin; Dose-Response Relationship, Drug; Fluoroquinolones; Gene Expression Regulation; Macrophages; Mice; Moxifloxacin; Quinolines | 2011 |
Impact of spores on the comparative efficacies of five antibiotics for treatment of Bacillus anthracis in an in vitro hollow fiber pharmacodynamic model.
Topics: Acetamides; Anti-Bacterial Agents; Aza Compounds; Bacillus anthracis; Ciprofloxacin; Doxycycline; Fluoroquinolones; Linezolid; Meropenem; Microbial Sensitivity Tests; Microbial Viability; Models, Biological; Moxifloxacin; Oxazolidinones; Predictive Value of Tests; Quinolines; Spores, Bacterial; Thienamycins; Viral Load | 2012 |
Photo quiz: A 36-year-old with recurrent conjunctivitis.
Topics: Administration, Topical; Adult; Anti-Bacterial Agents; Aza Compounds; Bacterial Typing Techniques; Bacteriological Techniques; Ciprofloxacin; Conjunctivitis; Corneal Transplantation; Fluoroquinolones; Gram-Negative Bacterial Infections; Humans; Male; Microbial Sensitivity Tests; Microscopy; Moxifloxacin; Paracoccus; Quinolines; Recurrence; Surgical Wound Infection | 2012 |
[In vitro antibiotic susceptibility to fluoroquinolones].
Topics: Acanthamoeba Keratitis; Anti-Bacterial Agents; Aza Compounds; Body Fluids; Ciprofloxacin; Colombia; Conjunctivitis, Bacterial; Drug Resistance, Multiple, Bacterial; Eye Infections, Bacterial; Eye Infections, Fungal; Eye Infections, Parasitic; Fluoroquinolones; Gatifloxacin; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Gram-Positive Bacteria; Gram-Positive Bacterial Infections; Humans; Keratitis; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Retrospective Studies | 2012 |
Adjunctive antibiotics in the treatment of acute bacterial endophthalmitis following cataract surgery.
Topics: Acute Disease; Administration, Oral; Anti-Bacterial Agents; Aqueous Humor; Aza Compounds; Bacteria; Cataract Extraction; Ciprofloxacin; Endophthalmitis; Eye Infections, Bacterial; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Postoperative Complications; Quinolines; Retrospective Studies; Vancomycin; Visual Acuity; Vitreous Body | 2012 |
Induction of mycobacterial resistance to quinolone class antimicrobials.
Topics: Anti-Infective Agents; Antitubercular Agents; Aza Compounds; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Gatifloxacin; Levofloxacin; Microbial Sensitivity Tests; Molecular Structure; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Quinolines | 2012 |
Comparative in vitro activity of sitafloxacin against bacteria isolated from Thai patients with urinary tract infections and lower respiratory tract infections.
Topics: Anti-Bacterial Agents; Aza Compounds; Bacteria; Ciprofloxacin; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Quinolines; Respiratory Tract Infections; Thailand; Urinary Tract Infections | 2012 |
Mass spectrometic study of speciation in aluminium-fluoroquinolone solutions.
Topics: Aluminum; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Fleroxacin; Fluoroquinolones; Humans; Intestinal Absorption; Models, Chemical; Moxifloxacin; Quinolines; Solutions; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry | 2012 |
Photodegradation of fluoroquinolones in surface water and antimicrobial activity of the photoproducts.
Topics: Anti-Infective Agents; Aza Compounds; Chromatography, High Pressure Liquid; Ciprofloxacin; Fluoroquinolones; Levofloxacin; Moxifloxacin; Ofloxacin; Photolysis; Quinolines; Tandem Mass Spectrometry | 2012 |
Evidence of in vivo prophage induction during Clostridium difficile infection.
Topics: Anti-Bacterial Agents; Aza Compounds; Base Sequence; Ciprofloxacin; Clostridioides difficile; Clostridium Infections; DNA, Viral; Feces; Fluoroquinolones; Genetic Variation; Genome, Viral; Humans; Levofloxacin; Lysogeny; Microbial Sensitivity Tests; Mitomycin; Molecular Sequence Data; Moxifloxacin; Myoviridae; Ofloxacin; Prophages; Quinolines; Sequence Analysis, DNA; Virus Activation | 2012 |
Infectious nontuberculous serpiginous choroiditis.
Topics: Adult; Anti-Infective Agents; Antibodies, Bacterial; Aza Compounds; Bartonella henselae; Cat-Scratch Disease; Choroiditis; Ciprofloxacin; Eye Infections, Bacterial; Fluorescein Angiography; Fluoroquinolones; Francisella tularensis; Humans; Immunoglobulin G; Male; Middle Aged; Moxifloxacin; Quinolines; Tularemia; Vision Disorders; Visual Acuity | 2012 |
Fluoroquinolone photodegradation influences specific basophil activation.
Topics: Adolescent; Adult; Aged; Aza Compounds; Basophils; Ciprofloxacin; Fluoroquinolones; Humans; Hypersensitivity, Immediate; Immunoglobulin E; Light; Middle Aged; Moxifloxacin; Photolysis; Quinolines; Young Adult | 2013 |
Outpatient therapy for fever and neutropenia is safe but implementation is the key.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Ciprofloxacin; Female; Fever; Fluoroquinolones; Humans; Male; Moxifloxacin; Neoplasms; Neutropenia; Quinolines | 2013 |
Fluoroquinolone susceptibility in Mycobacterium tuberculosis after pre-diagnosis exposure to older- versus newer-generation fluoroquinolones.
Topics: Adult; Aged; Anti-Bacterial Agents; Aza Compounds; Case-Control Studies; Ciprofloxacin; DNA Gyrase; Drug Resistance, Bacterial; Female; Fluoroquinolones; Gatifloxacin; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Quinolines; Tuberculosis | 2013 |
Risk of severe dysglycemia among diabetic patients receiving levofloxacin, ciprofloxacin, or moxifloxacin in Taiwan.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Cohort Studies; Diabetes Complications; Female; Fluoroquinolones; Humans; Hyperglycemia; Hypoglycemia; Levofloxacin; Male; Middle Aged; Moxifloxacin; Odds Ratio; Propensity Score; Quinolines; Taiwan | 2013 |
US-based emergency department visits for fluoroquinolone-associated hypersensitivity reactions.
Topics: Adult; Aged; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Drug-Related Side Effects and Adverse Reactions; Emergency Service, Hospital; Female; Fluoroquinolones; Humans; Hypersensitivity; Levofloxacin; Male; Middle Aged; Moxifloxacin; Quinolines; United States | 2013 |
Environmental photochemistry of fluoroquinolones in soil and in aqueous soil suspensions under solar light.
Topics: Anti-Bacterial Agents; Chromatography, High Pressure Liquid; Ciprofloxacin; Enrofloxacin; Fluoroquinolones; Levofloxacin; Moxifloxacin; Photolysis; Soil; Soil Pollutants; Sunlight; Suspensions; Water | 2014 |
[Fluoroquinolone associated myasthenia gravis exacerbation: clinical analysis of 9 cases].
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Myasthenia Gravis; Quinolines; Retrospective Studies; Young Adult | 2013 |
Spectrum of bacterial keratitis at a tertiary eye care centre in India.
Topics: Aza Compounds; Ciprofloxacin; Corneal Ulcer; Fluoroquinolones; Gatifloxacin; Gram-Positive Bacteria; Humans; India; Microbial Sensitivity Tests; Moxifloxacin; Pseudomonas aeruginosa; Quinolines; Staphylococcus aureus | 2013 |
Moxifloxacin in lower respiratory tract infections: in silico simulation of different bacterial resistance and drug exposure scenarios.
Topics: Area Under Curve; Bronchopneumonia; Ciprofloxacin; Community-Acquired Infections; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Moxifloxacin; Pneumococcal Infections; Respiratory Tract Infections; Streptococcus pneumoniae | 2014 |
Effect of fluoroquinolones on mitochondrial function in pancreatic beta cells.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Animals; Anti-Bacterial Agents; Aza Compounds; Cells, Cultured; Ciprofloxacin; Flavin-Adenine Dinucleotide; Fluoroquinolones; Gatifloxacin; Glucose; Insulin-Secreting Cells; Mice; Mice, Knockout; Microscopy, Electron, Transmission; Mitochondria; Moxifloxacin; NADP; Quinolines; Sulfonylurea Receptors | 2014 |
Risk of hepatotoxicity associated with fluoroquinolones: a national case-control safety study.
Topics: Adult; Aged; Alcoholism; Anti-Bacterial Agents; Aza Compounds; Case-Control Studies; Chemical and Drug Induced Liver Injury; Ciprofloxacin; Comorbidity; Data Interpretation, Statistical; Databases, Factual; Female; Fluoroquinolones; Hospitals, Veterans; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Patient Safety; Quinolines; Retrospective Studies; Risk Factors; Socioeconomic Factors; United States; United States Department of Veterans Affairs | 2014 |
Pharmacokinetics of sunitinib in combination with fluoroquinolones in rabbit model.
Topics: Administration, Oral; Animals; Anti-Bacterial Agents; Antineoplastic Agents; Aza Compounds; Biotransformation; Chromatography, High Pressure Liquid; Ciprofloxacin; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Enzyme Inhibitors; Fluoroquinolones; Indoles; Injections, Intravenous; Levofloxacin; Male; Models, Animal; Moxifloxacin; Polypharmacy; Protein Kinase Inhibitors; Pyrroles; Quinolines; Rabbits; Spectrophotometry, Ultraviolet; Sunitinib | 2013 |
Antibiotic resistance and capacity for biofilm formation of different bacteria isolated from endodontic infections associated with root-filled teeth.
Topics: Actinomyces; Actinomyces viscosus; Amoxicillin; Anti-Bacterial Agents; Biofilms; Ciprofloxacin; Clindamycin; Dental Pulp Diseases; Doxycycline; Drug Resistance, Bacterial; Enterococcus faecalis; Fluoroquinolones; Fosfomycin; Gentamicins; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Limosilactobacillus fermentum; Moxifloxacin; Penicillin G; Penicillin Resistance; Prevotella; Propionibacterium; Rifampin; Streptococcus mutans; Tetracycline Resistance; Tooth, Nonvital; Vancomycin Resistance | 2014 |
Degradation of fluoroquinolone antibiotics and identification of metabolites/transformation products by liquid chromatography-tandem mass spectrometry.
Topics: Anti-Bacterial Agents; Aza Compounds; Biotransformation; Chromatography, Liquid; Ciprofloxacin; Fluoroquinolones; Moxifloxacin; Norfloxacin; Ofloxacin; Photolysis; Quinolines; Tandem Mass Spectrometry | 2014 |
Heterogeneous photocatalysis of moxifloxacin in water: chemical transformation and ecotoxicity.
Topics: Anti-Bacterial Agents; Catalysis; Chlorophyta; Ciprofloxacin; Ecotoxicology; Fluoroquinolones; Moxifloxacin; Titanium; Ultraviolet Rays; Water Pollutants, Chemical | 2015 |
Biopharmaceutical characterization of nebulized antimicrobial agents in rats: 1. Ciprofloxacin, moxifloxacin, and grepafloxacin.
Topics: Administration, Inhalation; Aerosols; Animals; Anti-Bacterial Agents; Biopharmaceutics; Bronchoalveolar Lavage Fluid; Cell Line; Ciprofloxacin; Fluoroquinolones; Humans; Macrophages, Alveolar; Male; Moxifloxacin; Piperazines; Rats; Rats, Sprague-Dawley; Urea | 2014 |
The effect of some fluoroquinolone family members on biospeciation of copper(II), nickel(II) and zinc(II) ions in human plasma.
Topics: Ciprofloxacin; Coordination Complexes; Copper; Fluoroquinolones; Humans; Ions; Levofloxacin; Moxifloxacin; Nickel; Ofloxacin; Zinc | 2014 |
Bacillus anthracis GrlAV96A topoisomerase IV, a quinolone resistance mutation that does not affect the water-metal ion bridge.
Topics: Alanine; Anti-Bacterial Agents; Bacillus anthracis; Cations, Divalent; Ciprofloxacin; DNA Topoisomerase IV; DNA, Bacterial; Drug Resistance, Bacterial; Fluoroquinolones; Manganese; Models, Molecular; Moxifloxacin; Mutation; Nickel; Protein Subunits; Recombinant Proteins; Topoisomerase Inhibitors; Valine; Water | 2014 |
On the performance of multiway methods for simultaneous quantification of two fluoroquinolones in urine samples by fluorescence spectroscopy and second-order calibration strategies.
Topics: Algorithms; Anti-Bacterial Agents; Calibration; Ciprofloxacin; Fluoroquinolones; Humans; Least-Squares Analysis; Limit of Detection; Moxifloxacin; Spectrometry, Fluorescence | 2015 |
Risks of cardiac arrhythmia and mortality among patients using new-generation macrolides, fluoroquinolones, and β-lactam/β-lactamase inhibitors: a Taiwanese nationwide study.
Topics: Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Arrhythmias, Cardiac; Azithromycin; beta-Lactamase Inhibitors; Cardiovascular Diseases; Ciprofloxacin; Clarithromycin; Comorbidity; Female; Fluoroquinolones; Humans; Levofloxacin; Logistic Models; Male; Moxifloxacin; Risk; Taiwan | 2015 |
Concordance of Mycobacterium tuberculosis fluoroquinolone resistance testing: implications for treatment.
Topics: Ciprofloxacin; Dose-Response Relationship, Drug; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2015 |
Protease-Sensitive Inhibitory Activity of Cell-free Supernatant of Lactobacillus crispatus 156 Synergizes with Ciprofloxacin, Moxifloxacin and Streptomycin Against Pseudomonas aeruginosa: An In Vitro Study.
Topics: Anti-Bacterial Agents; Chemical Phenomena; Ciprofloxacin; Culture Media, Conditioned; DNA, Bacterial; Drug Synergism; Female; Fluoroquinolones; Hot Temperature; Humans; Hydrogen-Ion Concentration; Lactobacillus; Microbial Sensitivity Tests; Moxifloxacin; Peptide Hydrolases; Pseudomonas aeruginosa; Sequence Analysis, DNA; Streptomycin; Urinary Tract Infections; Vagina | 2015 |
Release of Ciprofloxacin and Moxifloxacin From Daily Disposable Contact Lenses From an In Vitro Eye Model.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Contact Lenses, Hydrophilic; Disposable Equipment; Drug Delivery Systems; Eye Infections, Bacterial; Fluoroquinolones; Humans; Moxifloxacin | 2015 |
Fluoroquinolone use delays tuberculosis treatment despite immediate mycobacteriology study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Ciprofloxacin; Community-Acquired Infections; Female; Fluoroquinolones; Follow-Up Studies; Humans; Levofloxacin; Linear Models; Longitudinal Studies; Male; Middle Aged; Moxifloxacin; Multivariate Analysis; Mycobacterium tuberculosis; Ofloxacin; Pneumonia, Bacterial; Taiwan; Tuberculosis, Pulmonary; Young Adult | 2015 |
RX-P873, a Novel Protein Synthesis Inhibitor, Accumulates in Human THP-1 Monocytes and Is Active against Intracellular Infections by Gram-Positive (Staphylococcus aureus) and Gram-Negative (Pseudomonas aeruginosa) Bacteria.
Topics: Anti-Bacterial Agents; Ceftazidime; Cells, Cultured; Ciprofloxacin; Daptomycin; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Guanidines; Humans; Microbial Sensitivity Tests; Monocytes; Moxifloxacin; Protein Synthesis Inhibitors; Pseudomonas aeruginosa; Pseudomonas Infections; Pyrimidinones; Staphylococcal Infections; Staphylococcus aureus; Vancomycin | 2015 |
An in vitro Comparison of Endodontic Medicaments Propolis and Calcium Hydroxide alone and in Combination with Ciprofloxacin and Moxifloxacin against Enterococcus Faecalis.
Topics: Anti-Bacterial Agents; Bacteriological Techniques; Calcium Hydroxide; Ciprofloxacin; Drug Combinations; Drug Synergism; Enterococcus faecalis; Fluoroquinolones; Humans; Materials Testing; Moxifloxacin; Propolis; Root Canal Irrigants; Time Factors | 2015 |
Moxifloxacin and ciprofloxacin induces S-phase arrest and augments apoptotic effects of cisplatin in human pancreatic cancer cells via ERK activation.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Ciprofloxacin; Cisplatin; Drug Synergism; Fluoroquinolones; Gene Expression Regulation, Neoplastic; Humans; MAP Kinase Signaling System; Moxifloxacin; Pancreatic Neoplasms; S Phase | 2015 |
Simultaneous determination of fluoroquinolones in environmental water by liquid chromatography-tandem mass spectrometry with direct injection: A green approach.
Topics: Anti-Bacterial Agents; Brazil; Chromatography, Liquid; Ciprofloxacin; Enrofloxacin; Fluoroquinolones; Fresh Water; Gemifloxacin; Green Chemistry Technology; Moxifloxacin; Naphthyridines; Norfloxacin; Ofloxacin; Tandem Mass Spectrometry; Wastewater; Water Pollutants, Chemical | 2015 |
Antibiotic Resistance among Clinical Ureaplasma Isolates Recovered from Neonates in England and Wales between 2007 and 2013.
Topics: Anti-Bacterial Agents; Chloramphenicol; Ciprofloxacin; Drug Resistance, Bacterial; England; Epidemiological Monitoring; Fluoroquinolones; Gentamicins; Humans; Infant; Infant, Newborn; Levofloxacin; Macrolides; Microbial Sensitivity Tests; Moxifloxacin; Retrospective Studies; Tetracycline; Ureaplasma; Ureaplasma Infections; Wales | 2016 |
In vitro antimicrobial susceptibility of Helicobacter pylori to nine antibiotics currently used in Central Italy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Ampicillin; Anti-Bacterial Agents; Child; Ciprofloxacin; Clarithromycin; Drug Resistance, Multiple, Bacterial; Dyspepsia; Female; Fluoroquinolones; Gastric Fundus; Helicobacter Infections; Helicobacter pylori; Humans; Italy; Levofloxacin; Male; Metronidazole; Microbial Sensitivity Tests; Middle Aged; Moxifloxacin; Pyloric Antrum; Rifabutin; Tetracycline; Young Adult | 2016 |
Fluoroquinolone interactions with Mycobacterium tuberculosis gyrase: Enhancing drug activity against wild-type and resistant gyrase.
Topics: Anti-Bacterial Agents; Ciprofloxacin; DNA Gyrase; Drug Resistance, Bacterial; Fluoroquinolones; Metals; Moxifloxacin; Mycobacterium tuberculosis; Water | 2016 |
Effect of Fluoroquinolones and Macrolides on Eradication and Resistance of Haemophilus influenzae in Chronic Obstructive Pulmonary Disease.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Fluoroquinolones; Haemophilus influenzae; Levofloxacin; Macrolides; Microbial Sensitivity Tests; Moxifloxacin; Pulmonary Disease, Chronic Obstructive | 2016 |
Comparative Activity of Ciprofloxacin, Levofloxacin and Moxifloxacin against Klebsiella pneumoniae, Pseudomonas aeruginosa and Stenotrophomonas maltophilia Assessed by Minimum Inhibitory Concentrations and Time-Kill Studies.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Fluoroquinolones; Inhibitory Concentration 50; Klebsiella pneumoniae; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Pseudomonas aeruginosa; Stenotrophomonas maltophilia | 2016 |
Increasing resistance to fluoroquinolones among Haemophilus species in Southern Taiwan.
Topics: Anti-Bacterial Agents; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Haemophilus influenzae; Haemophilus parainfluenzae; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Taiwan | 2017 |
Role of gyrB Mutations in Pre-extensively and Extensively Drug-Resistant Tuberculosis in Thai Clinical Isolates.
Topics: Aminopyridines; Antitubercular Agents; Ciprofloxacin; DNA Gyrase; Drug Resistance, Bacterial; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Gatifloxacin; Gene Expression; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mutation; Mycobacterium tuberculosis; Ofloxacin; Thailand; Tuberculosis, Pulmonary | 2016 |
Penetrating Orbital Injury From a Needlefish.
Topics: Adult; Ampicillin; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Beloniformes; Cefazolin; Ciprofloxacin; Diplopia; Diving; Fluoroquinolones; Foreign Bodies; Humans; Male; Military Personnel; Moxifloxacin; Prednisone; Prefrontal Cortex; Tomography, X-Ray Computed; Wounds, Penetrating | 2016 |
Effect of fluoroquinolones on melanogenesis in normal human melanocytes HEMn-DP: a comparative in vitro study.
Topics: Anti-Bacterial Agents; Cell Line; Cell Survival; Ciprofloxacin; Dermatitis, Phototoxic; Epidermal Cells; Epidermis; Fluoroquinolones; Humans; Melanins; Melanocytes; Monophenol Monooxygenase; Moxifloxacin; Spectrophotometry | 2017 |
Two Clusters of Fluoroquinolone and Clindamycin-Resistant Clostridium difficile PCR Ribotype 001 Strain Recognized by Capillary Electrophoresis Ribotyping and Multilocus Variable Tandem Repeat Analysis.
Topics: Aged; Amino Acid Substitution; Anti-Bacterial Agents; Ciprofloxacin; Clindamycin; Clostridioides difficile; Clostridium Infections; Czech Republic; DNA Gyrase; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Electrophoresis, Capillary; Female; Fluoroquinolones; Gene Expression; Humans; Male; Methyltransferases; Metronidazole; Microbial Sensitivity Tests; Minisatellite Repeats; Moxifloxacin; Multilocus Sequence Typing; Retrospective Studies; Ribotyping; Tertiary Care Centers; Vancomycin | 2017 |
Moxifloxacin versus levofloxacin or ciprofloxacin prophylaxis in acute myeloid leukemia patients receiving chemotherapy.
Topics: Adult; Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Ciprofloxacin; Clostridioides difficile; Enterocolitis, Pseudomembranous; Female; Fluoroquinolones; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Levofloxacin; Male; Middle Aged; Moxifloxacin; Neutropenia; Randomized Controlled Trials as Topic; Retrospective Studies | 2017 |
Penetration of 0.3% ciprofloxacin, 0.3% ofloxacin, and 0.5% moxifloxacin into the cornea and aqueous humor of enucleated human eyes.
Topics: Aqueous Humor; Bayes Theorem; Cadaver; Ciprofloxacin; Cornea; Eye Enucleation; Fluoroquinolones; Humans; Moxifloxacin; Ofloxacin | 2017 |
Ozone pretreatment of process waste water generated in course of fluoroquinolone production.
Topics: Anti-Bacterial Agents; Chromatography, Liquid; Ciprofloxacin; Fluoroquinolones; Kinetics; Mass Spectrometry; Moxifloxacin; Ozone; Waste Disposal, Fluid; Wastewater; Water; Water Pollutants, Chemical | 2017 |
Machine learning for classifying tuberculosis drug-resistance from DNA sequencing data.
Topics: Antitubercular Agents; Ciprofloxacin; Ethambutol; Humans; Isoniazid; Machine Learning; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Pyrazinamide; Rifampin; Sequence Analysis, DNA; Streptomycin; Tuberculosis, Multidrug-Resistant | 2018 |
Liquid chromatography-tandem mass spectrometry for the quantification of moxifloxacin, ciprofloxacin, daptomycin, caspofungin, and isavuconazole in human plasma.
Topics: Anti-Bacterial Agents; Antifungal Agents; Caspofungin; Chromatography, High Pressure Liquid; Ciprofloxacin; Daptomycin; Echinocandins; Fluoroquinolones; Humans; Limit of Detection; Lipopeptides; Moxifloxacin; Nitriles; Plasma; Pyridines; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Triazoles | 2018 |
In vitro effects of ciprofloxacin, levofloxacin and moxifloxacin on Mycobacterium tuberculosis isolates.
Topics: Antitubercular Agents; Ciprofloxacin; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium tuberculosis; Tuberculosis; Tuberculosis, Multidrug-Resistant; Turkey | 2018 |
Association of oral ciprofloxacin, levofloxacin, ofloxacin and moxifloxacin with the risk of serious ventricular arrhythmia: a nationwide cohort study in Korea.
Topics: Administration, Oral; Aged; Anti-Bacterial Agents; Arrhythmias, Cardiac; Cefixime; Ciprofloxacin; Cohort Studies; Female; Fluoroquinolones; Heart Arrest; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Protective Factors; Republic of Korea; Risk Factors; Tachycardia, Ventricular; Ventricular Fibrillation; Ventricular Flutter | 2018 |
The Association of Antibiotic Stewardship With Fluoroquinolone Prescribing in Michigan Hospitals: A Multi-hospital Cohort Study.
Topics: Aged; Anti-Bacterial Agents; Antimicrobial Stewardship; Ciprofloxacin; Clostridium Infections; Cohort Studies; Drug Prescriptions; Drug Resistance, Bacterial; Female; Fluoroquinolones; Hospitals; Humans; Levofloxacin; Male; Michigan; Moxifloxacin; Pneumonia; Retrospective Studies; Risk; Surveys and Questionnaires | 2019 |
Assessing fluoroquinolone-associated aortic aneurysm and dissection: Data mining of the public version of the FDA adverse event reporting system.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Aortic Aneurysm, Thoracic; Aortic Dissection; Bayes Theorem; Child; Child, Preschool; Ciprofloxacin; Data Mining; Female; Fluoroquinolones; Humans; Infant; Infant, Newborn; Levofloxacin; Male; Middle Aged; Moxifloxacin; Pharmacovigilance; United States; United States Food and Drug Administration; Young Adult | 2019 |
Association Between Peripheral Neuropathy and Exposure to Oral Fluoroquinolone or Amoxicillin-Clavulanate Therapy.
Topics: Administration, Oral; Adult; Age Factors; Aged; Aged, 80 and over; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Case-Control Studies; Ciprofloxacin; Female; Fluoroquinolones; Humans; Incidence; Levofloxacin; Male; Middle Aged; Moxifloxacin; Norfloxacin; Ofloxacin; Peripheral Nervous System Diseases; Risk Factors; Sex Factors; United Kingdom | 2019 |
Fluoroquinolones in Drug-Resistant Tuberculosis: Culture Conversion and Pharmacokinetic/Pharmacodynamic Target Attainment To Guide Dose Selection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antitubercular Agents; Ciprofloxacin; Dose-Response Relationship, Drug; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Microbial Sensitivity Tests; Middle Aged; Models, Biological; Moxifloxacin; Ofloxacin; Retrospective Studies; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult | 2019 |
Management of Nocardia Interface Keratitis After Descemet Membrane Endothelial Keratoplasty.
Topics: Administration, Ophthalmic; Aged; Anti-Bacterial Agents; Atropine; Ciprofloxacin; Combined Modality Therapy; Descemet Stripping Endothelial Keratoplasty; Drug Therapy, Combination; Eye Infections, Bacterial; Humans; Keratitis; Male; Moxifloxacin; Nocardia asteroides; Nocardia Infections; Ophthalmic Solutions; Reoperation; Retrospective Studies; Visual Acuity | 2019 |
Development and validation of a UPLC-MS/MS method for simultaneous quantification of levofloxacin, ciprofloxacin, moxifloxacin and rifampicin in human plasma: Application to the therapeutic drug monitoring in osteoarticular infections.
Topics: Chromatography, High Pressure Liquid; Ciprofloxacin; Drug Monitoring; Female; Humans; Levofloxacin; Limit of Detection; Male; Middle Aged; Moxifloxacin; Plasma; Reproducibility of Results; Rifampin; Tandem Mass Spectrometry | 2020 |
Ciprofloxacin Corneal Deposits With Complete Dissipation After Switching to Moxifloxacin.
Topics: Administration, Ophthalmic; Aged; Anti-Bacterial Agents; Chemical Precipitation; Ciprofloxacin; Cornea; Corneal Ulcer; Drug Substitution; Eye Infections, Bacterial; Humans; Male; Moxifloxacin; Ophthalmic Solutions; Pseudomonas Infections; Slit Lamp Microscopy | 2020 |
The tcdA-negative and tcdB-positive Clostridium difficile ST81 clone exhibits a high level of resistance to fluoroquinolones: a multi-centre study in Beijing, China.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Bacterial Toxins; China; Ciprofloxacin; Clostridioides difficile; Clostridium Infections; DNA Gyrase; Drug Resistance, Bacterial; Enterotoxins; Fluoroquinolones; Humans; Levofloxacin; Metronidazole; Microbial Sensitivity Tests; Molecular Epidemiology; Molecular Typing; Moxifloxacin; Vancomycin | 2020 |
Response to: letter to the editor: consideration on 'an evaluation of reports of ciprofloxacin, levofloxacin, and moxifloxacin association neuropsychiatric toxicities, long-term disability, and aortic aneurysms/dissections disseminated by the food and dru
Topics: Animals; Aortic Aneurysm; Ciprofloxacin; Dissection; Humans; Idiopathic Pulmonary Fibrosis; Levofloxacin; Moxifloxacin; United States; United States Food and Drug Administration | 2020 |
Letter to the Editor: Consideration on "An evaluation of reports of ciprofloxacin, levofloxacin, and moxifloxacin- association neuropsychiatric toxicities, long-term disability, and aortic aneurysms/dissections disseminated by the Food and Drug Administra
Topics: Aortic Aneurysm; Ciprofloxacin; Dissection; Fluoroquinolones; Humans; Levofloxacin; Moxifloxacin; United States; United States Food and Drug Administration | 2020 |
Ciprofloxacin and moxifloxacin could interact with SARS-CoV-2 protease: preliminary in silico analysis.
Topics: Antiviral Agents; Binding Sites; Chloroquine; Ciprofloxacin; Coronavirus 3C Proteases; COVID-19; COVID-19 Drug Treatment; Humans; Molecular Docking Simulation; Molecular Dynamics Simulation; Moxifloxacin; Nelfinavir; Protein Binding; SARS-CoV-2 | 2020 |
Fluoroquinolone Antibiotics Exhibit Low Antiviral Activity against SARS-CoV-2 and MERS-CoV.
Topics: A549 Cells; Angiotensin-Converting Enzyme 2; Animals; Anti-Bacterial Agents; Antiviral Agents; Cell Line; Chlorocebus aethiops; Ciprofloxacin; Coronavirus Infections; COVID-19 Drug Treatment; Enoxacin; Fluoroquinolones; Humans; Levofloxacin; Middle East Respiratory Syndrome Coronavirus; Moxifloxacin; SARS-CoV-2; Vero Cells | 2020 |
Basophil activation test in the diagnosis of hypersensitivity reactions to quinolones in a real-life setting.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Basophil Degranulation Test; Ciprofloxacin; Drug Hypersensitivity; Female; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Norfloxacin; Quinolones; Skin Tests; Young Adult | 2021 |
Comparison of
Topics: Anti-Infective Agents; Ciprofloxacin; Fluoroquinolones; Humans; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium Infections, Nontuberculous; Nontuberculous Mycobacteria | 2021 |
Emergence of fluoroquinolone resistance and possible mechanisms in clinical isolates of Stenotrophomonas maltophilia from Iran.
Topics: Alleles; Anti-Bacterial Agents; Bacterial Proteins; Ciprofloxacin; Drug Resistance, Bacterial; Fluoroquinolones; Iran; Moxifloxacin; Stenotrophomonas maltophilia | 2021 |
A VigiBase descriptive study of fluoroquinolone induced disabling and potentially permanent musculoskeletal and connective tissue disorders.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Adverse Drug Reaction Reporting Systems; Arthralgia; Ciprofloxacin; Connective Tissue Diseases; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Female; Fluoroquinolones; Humans; Levofloxacin; Male; Middle Aged; Moxifloxacin; Musculoskeletal Diseases; Myalgia; Norfloxacin; Ofloxacin; Pain; Risk Factors; Tendinopathy; Tendons; Young Adult | 2021 |
In vitro evaluation of antimicrobial resistance selection in Neisseria gonorrhoeae.
Topics: Anti-Bacterial Agents; Azithromycin; Ceftriaxone; Ciprofloxacin; Doxycycline; Drug Resistance, Multiple, Bacterial; Ertapenem; Gentamicins; Gonorrhea; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Neisseria gonorrhoeae | 2021 |
Investigation of the effects of three different generations of fluoroquinolone derivatives on antioxidant and immunotoxic enzyme levels in different rat tissues.
Topics: Adenosine Deaminase; Animals; Antioxidants; Aspartate Aminotransferases; Catalase; Ciprofloxacin; COVID-19; Creatinine; Fluoroquinolones; Glucose; Glutathione; Glutathione Peroxidase; Levofloxacin; Lipid Peroxidation; Malondialdehyde; Moxifloxacin; Nalidixic Acid; Oxidative Stress; Peroxidase; Rats; Rats, Wistar; SARS-CoV-2; Superoxide Dismutase; Triglycerides | 2022 |
Corynebacterium Keratitis: Pure Versus Mixed Infection and Antibiotic Susceptibility Patterns From Different Tertiary Eye Care Centers.
Topics: Anti-Bacterial Agents; Cefazolin; Ciprofloxacin; Coinfection; Corynebacterium; Eye Infections, Bacterial; Fluoroquinolones; Gatifloxacin; Humans; Keratitis; Microbial Sensitivity Tests; Moxifloxacin; Ofloxacin; Retrospective Studies; Tertiary Care Centers; Vancomycin | 2022 |
A molecularly imprinted polymer nanoparticle-based surface plasmon resonance sensor platform for antibiotic detection in river water and milk.
Topics: Allergens; Animals; Anti-Bacterial Agents; Ciprofloxacin; Milk; Molecular Imprinting; Molecularly Imprinted Polymers; Moxifloxacin; Nanoparticles; Ofloxacin; Rivers; Surface Plasmon Resonance; Water | 2022 |
Antibiotics and antimycotics in waste water treatment plants: Concentrations, removal efficiency, spatial and temporal variations, prediction, and ecological risk assessment.
Topics: Anti-Bacterial Agents; Ciprofloxacin; Clotrimazole; Environmental Monitoring; Moxifloxacin; Norfloxacin; Ofloxacin; Pefloxacin; Risk Assessment; Sewage; Waste Disposal, Fluid; Wastewater; Water Pollutants, Chemical; Water Purification | 2022 |
Introduction of maltodextrin nanosponges as green extraction phases: Magnetic solid phase extraction of fluoroquinolones.
Topics: Chromatography, High Pressure Liquid; Ciprofloxacin; Enrofloxacin; Fluoroquinolones; Magnetic Phenomena; Moxifloxacin; Ofloxacin; Polysaccharides; Solid Phase Extraction; Wastewater; Water | 2022 |
Association between initiation of fluoroquinolones and hospital admission or emergency department visit for suicidality: population based cohort study.
Topics: Adult; Anti-Bacterial Agents; Azithromycin; Ciprofloxacin; Cohort Studies; Emergency Service, Hospital; Fluoroquinolones; Gatifloxacin; Gemifloxacin; Hospitals; Humans; Levofloxacin; Moxifloxacin; Norfloxacin; Retrospective Studies; Suicidal Ideation; Suicide; Trimethoprim, Sulfamethoxazole Drug Combination; Urinary Tract Infections | 2022 |
Hotspots sequences of gyrA, gyrB, parC, and parE genes encoded for fluoroquinolones resistance from local Salmonella Typhi strains in Jakarta.
Topics: Amino Acids; Anti-Bacterial Agents; Ciprofloxacin; DNA Gyrase; DNA Topoisomerase IV; Drug Resistance, Bacterial; Fluoroquinolones; Humans; Levofloxacin; Microbial Sensitivity Tests; Moxifloxacin; Nalidixic Acid; Quinolones; Salmonella; Salmonella enterica; Salmonella typhi; Typhoid Fever | 2022 |
Fluoroquinolone resistance in bacterial isolates from ocular infections: Trend in antibiotic susceptibility patterns between 2005-2020.
Topics: Anti-Bacterial Agents; Cefuroxime; Ciprofloxacin; Colistin; Eye Infections; Fluoroquinolones; Gatifloxacin; Humans; Longitudinal Studies; Moxifloxacin; Ofloxacin; Retrospective Studies | 2022 |
Impact of fluoroquinolones and aminoglycosides on P. aeruginosa virulence factor production and cytotoxicity.
Topics: ADP Ribose Transferases; Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; Bacterial Proteins; Ciprofloxacin; Fluoroquinolones; Genotype; Humans; Moxifloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Virulence Factors | 2022 |
Real-Time Impedance-Based Monitoring of the Growth and Inhibition of Osteomyelitis Biofilm Pathogen
Topics: Anti-Bacterial Agents; Biofilms; Ciprofloxacin; Diphosphonates; Durapatite; Electric Impedance; Etidronic Acid; Humans; Microbial Sensitivity Tests; Moxifloxacin; Osteomyelitis; Staphylococcal Infections; Staphylococcus aureus | 2023 |
Design and synthesis of novel cytotoxic fluoroquinolone analogs through topoisomerase inhibition, cell cycle arrest, and apoptosis.
Topics: Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Ciprofloxacin; Drug Screening Assays, Antitumor; Fluoroquinolones; Humans; Molecular Structure; Moxifloxacin; Ofloxacin; Structure-Activity Relationship | 2023 |
Antibiotic Resistance among Fusobacterium, Capnocytophaga, and Leptotrichia Species of the Oral Cavity.
Topics: Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti-Infective Agents; Capnocytophaga; Ciprofloxacin; Clindamycin; Doxycycline; Drug Resistance, Bacterial; Fusobacterium; Humans; Leptothrix; Leptotrichia; Metronidazole; Microbial Sensitivity Tests; Moxifloxacin; Periodontal Diseases | 2023 |
[Evaluation of Antimicrobial Susceptibilities of Rapidly Growing Mycobacteria].
Topics: Amikacin; Anti-Bacterial Agents; Cefoxitin; Ciprofloxacin; Clarithromycin; Doxycycline; Humans; Imipenem; Linezolid; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium; Mycobacterium Infections, Nontuberculous; Nontuberculous Mycobacteria; Tobramycin | 2023 |
In-Class Cross-Reactivity among Hospitalized Patients with Hypersensitivity Reactions to Fluoroquinolones.
Topics: Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Fluoroquinolones; Humans; Hypersensitivity; Levofloxacin; Moxifloxacin; Ofloxacin; Quinolines | 2023 |
Long-term Cardiovascular Adverse Events Induced by Fluoroquinolones: A Retrospective Case-control Study.
Topics: Case-Control Studies; Ciprofloxacin; Fluoroquinolones; Heart Valve Diseases; Humans; Levofloxacin; Moxifloxacin; Retrospective Studies | 2023 |